CA1321542C - Drug, delivery compositions and methods - Google Patents

Abstract

DRUG DELIVERY COMPOSITIONS AND METHODS
Abstract of the Disclosure Drug delivery compositions yield new and unexpected degrees of stabilization, solubilization and delivery of incorporated medicaments, drugs, or other physiologically-active compounds. The composi-tions enable administration of drugs and other medic-ally useful compounds via a variety of routes. More particularly, a drug delivery system or composition including one or more monomeric or polymerized sur-face active agents allows for rapid dissolution and smooth liberation of any desired incorporated drug or combinations, and the method of preparing the drug composition. In one embodiment, the physiologically-active compound is encapsulated by a coacervate-derived film, and the finished product is suitable for trans-mucosal administration. Other formulations of this invention may be administered via inhalation, oral, parenteral and by transdermal routes.

Description

DRUG DELIVERY COMPOSITIONS AND METHODS
FIELD OF THE INVENTION
The present invention relates to a stable drug delivery composition in oral dosage form or cap-able of new and unexpected stabilization, solubiliza-tion and delivery of stable drug components in paren-teral form at the pH of body tissue. More particular-ly, the present invention is directed to a drug deli-very system or composition that allows for rapid dis-solution and smooth liberation of any desired drugeither orally or parenterally without precipitation, and the method of preparing the drug composition. In accordance with one embodiment of the present inven-tion, liposomes and their contents can be enveloped in a coacervate-based film to prevent disintegration of liposome vehicles.
BACKGROUND OF THE INVENTION
Drugs now in common use often require formu-lation compromises in order to prepare the marketed product. Thus, many parenteral compositions must be prepared using the salt of the parent compound and an excessive pH.
The instability of many useful drugs and other useful medical compositions poses other formula-tion problems. At present, emulsions, microemulsionsand liposomes constitute the principal approaches to these problems. While such dosage forms are an advanc -2- ~ ~ 3 2 ~ ~ ~ 2 64267-638 over older forms, they are often associated with er-ratic bioavailability and instability of their own.
The hereln disclosed lnventlon comprlses a method to prepare composltlons and compositions which deliver medically useful compositions effectively.
The method is based upon the use of a non-toxic aqueous coacervate; said method produces stable microemulsions comprised Oe particles ln which one or more pharmaceu-tical components have been incorporated. Through the process of this invention particles are enveloped by a coacervate-based film. The composltions of this invention may be administered orally, parenterally or by tlssue absorptlon, as required.
The disclosed method enables the preparation of partlcles of any desieed size and any degree of particle surface film hardness, any number of eoacer-vate-derived films of any deslred thickness, or any combination oE particle sizes and surface hardnesses.
In preferred compositlons prepared by the disclosed invention, the particle cize is about 1 micron or less. The pharmaceutical component(s) may be any water soluble or water lnsoluble medically useful composltion or combinations of such composltions.
The inventor has previously disclosed compo-sitions based on a coacervate system using albuminand lecithln as principal components of the system.
However, by polymerizing one or both of these compon-ents, the inventor has not only simplified the method but unexpectedly peoduced a preparatlon with vastly improved encapsulating capabillty. Details of thls lmProvement are presented in the Experiments Section.

~P
L~

~ - 3 - 64267-638 1 3 ~

DEscl~IplrloN OF TIIE PnIOR A~T
_ _ While there are apparent slml1aritles to tlle inventor's prlor art, thls applicatlon dlffers slgnlflcantly ln several lmportant aspects. Thus, encapsulation is a fundamental aspect of the lnventor's prlor art and the present lnvention. IIowever, by polymerizlng one or more of the surfactants used in the present lnventlon, and/or by modlEylng the pre-vlously dlsclosed processes, the proportlon Oe the pharmaceutlcal component lncorporated ln the present formulatlon 18 approxlmately two to slx tlmes greater than that of foemulatlons dlsclosed earller.
The intravenous dellvery o~ many pharmaceu-tlcal preparatlons has been 1lmited to the use oE
aqueous slngu1ar systems, as discuæsed, based upon the salt oE a parent compound and/or the dissolutlon of the compound by agents such a~ a propylene glycol or alcohol. Other known syqtems whlch functlon prl-marlly as blood æub3tltutes, however, are able to so1ubl1lze and dellver drugæ lnfused thereln to a restrlcted degree. U.S. Patent No. 4,343,797 dlscloses a method of preparlng a synthetlc blood substltute based upon a two-phase heterogeneous physico-chemical sy~tem which provldes Eor oxygen transport and other phyælologlcal functlons lnherent to whole natural blood. In U.S. Patent No. 4,439,424 a preferred syn-thetlc blood composltlon comprlses albumln, water, sodlum chlorlde, urea and leclthln ln the form of a two-phase coacervate system whlch ls rendered lsotonlc wlth human blood by the addltlon oE controlled amounts Oe the sodium chlorlde. U.S. Patent Nos. 4,558,032, 4,539,204 and 4,596,178 relate to gelatln based syn-. ~ .
.

-4- ~ 1 3 ?, ~
thetic blood substitutes based upon a two-phase coa-cervate system utilizing respectively, gelatin and acacia two gelatins modified fluid gelatins of dif-ferent isoelectric points; and gelatin or modified gelatin and lecithin. U.S. Patent No. 4,547,490 discloses a further coacervate synthetic blood derived from an aqueous solution containing albumin, sodium chloride and lecithin in a nonpolar or semipolar sol-vent.
These known products have been found to be capable of carr~ing drugs, but have been designed to serve as a resuscitative fluid much in the manner of whole natural blood. One of the principal formulation problems successfully addressed by the aforementioned patents is maintenance of the structure and integrity of the microparticles (synthocytes) which comprise the composition.
The hemoglobin component of this composition (i.e., stroma-free hemoglobin, pyridoxilated-poly-merized hemoglobin, liposome encapsulated hemoglobin and the like) remains functional and encapsulated within the microparticles (synthocytes) until the particles are metabolized and eliminated from the body. Encapsulation of the hemoglobin component not only preserves functionality but reduces or eliminates endotoxic reactions associated with non-encapsulated hemoglobin. The term "synthocy~e" as used in this specification refers to the microparticles of this invention, the particles being about 1 micron or less in any single dimension when administered parenterally, and comprised of a coacervate-based matrix which con-tains the active component~s); and a coacervate-based film which envelopes the contents of the microparticle and constitutes the outer surface of the particle.
The enveloping film may be comprised of one or more layers as required to prepare the desired composition.

- 13~..r~2 In this specification the terms "particle", "syntho-cyte" and "microparticle" will be used interchangeably.
Another example of a coacervate-based system is disclosed in International application PCT/US85/00859, published November 21, 1985, relating to an oral dosage composition and method of preparation to enable the oral administration of insulin. The problems addressed by the disclosed coacervate system, however, include the need for protection of the insulin against degradation by enzymes, and factors such as the acid-base balance and other gastrointestinal con-ditions and processes. The coacervate-based film envelopes each individual insulin molecule to inhibit the interaction between the insulin component and the degrading conditions.
The prior art describing the liposome tech-nology includes the following: The ~sh and Hider U.S. Patent No. 4,448,765 filed July 3, 1979 entitled LIPOSOMES AND THEIR USE IN TREATING HUMAN OR OT~ER
MAMMALIAN PATIENTS, describes microvesicles which are reportedly stabilized by the incorporation of a polymer having at least six atoms attached to the backbone tbereof; said vesicles incorporating a physioplogic-ally-active substance. Kelly U.S. Patent No. 4,356,167 ~; 25 entitled LIPOSOME DRUG DELIVERY SYSTEMS, filed June 22, 1981, describes a liposome medicament delivery system wherein the medicament is in an aliphatic li-quid-sterol-water lamellae. The lipid may be a sodium or potassium salt of a C4 to Clg fatty acid and the sterol may be cholesterol. Kao, Y. and Loo, T., Phar-macological Disposition of Negatively Charged Phospho-lipid Vesicles in Rats, J. of Pharm. Sci. 59;11, ~ 1980, pp. 1338-1343 contains a report of experiments -~ which investigated the pharmacological disposition of four negatively charged phospholipid vesicles.
Gregoriadis, G., the Carrier Potential of Liposomes ~ in Biology and Medicine; N.E. J. of Med. Vol. 295, .'' ~

.
, .

-6- ~ 1 3 2 1 ~ ~ ~ 64267-638 No. 13, 1976, descrlbes the use of liposomes to carry a large variety oE blologically intere~ting composl-tions including hormones, drugs, sterolds, vitamins, viruses and other compositlons such as histamine.
Doucet, D., et al; Oxygen ~inding Oe Artificial Ery-throcytes, in Proceedings of Int. Soc. of ArtiE. Or-gans, 5, (Supp~ 1981, pp. 392-395, describes the use of liposomes to lncorporate a concentrated hemoglobin solution. Gaber, ~., et al; Encapsulation of Hemo-globln in Phospholipld Vesicles, FEBS Letters, Vol.
153, 2, 1983, pp. 285-287, describes a method to encap-sulate hemoglobin in phospholipid vesicles. Gruner, S., Novel Multilayerea Lipid Vesicles: Comparison of Physical Characteristics of Multllamellar Llposomes and Stable Plurilamellar Vesicles, Biocheml~try, 24, 1985, 2833-2842, discusses the effects of osmotic compression on the productlon of various liposome compositions; Szebeni, J. et al.; Encapsulation of Hemoglobin in Phospholipid Liposome; Characterization and Stability; Biochemistry: 24, 1985, 2827-2832, ceports the encapsulation of hemoglobin in liposomes Oe different lipid composition. Blood Pollcy and Technology; Office of Technology Assessment, U.S.
Congress, U.S. Government Pelnting Office, 1985, pp.
146-151, reports the methods of formulatlon and the difficultles encountered in uslng liposome based blood ~ubstitutes.
It is important to emphasize that liposomes dlffer Eeom the coacervate preparations previously discussed and herein dlsclosed in mode Oe manufacture, and in physlcal and structural properties, Coacervates are used in the preparation of the compositions of this invention.

~'' ' ~' ~

- 1321~2 There are Eundamental dlfEerence~ between thls lnvention and the lnventor's prior art. In some lnstances, e.g., the blood ~ubstitute formulatlons, are based on preclsely opposlte theoretlcal and Eunc-tlonal characterlstlcs. Thus, the blood substltute formulatlons are based squarely on a gas exchange system. In this lnstance, oxygen is absorbed by the hemoglobln component oE the synthocyte and released ; ; Erom the hemoglobln to the tlssues according to oxygen ~ tenslons. Thls phenomena 18 represented ln whole , ~

'~,,: : :
,....

, ,"., ~,.'~,: ~ : :
, ~,, ~:
,, ", , ~,,: :
.,,,,~ "~,~,"~

, ~ , 3~
, ': ':
, ' ' ' ". ' . ,' ~,,, ' ' .

! "~ ' .

.

-8- 1321~
blood and some blood substitutes by a sigmoid curve.
In contrast, in this invention, the drug is released from encapsulation; the release can be represented by a straight line function Ol- by an exponential rate of release.
Further, the inventor's blood substitutes are specifically formulated to maintain the hemoglobin component in an encapsulated state up to the time the ; synthocyte and its contents are metabolized. In the present invention, the formulations are designed to release the drug from the synthocyte promptly after administration. The present invention provides for a variety of routes of administration; the inventor's blood substitutes are restricted to intravenous injec-tion.
SUMMARY OF THE INVENTION
The method of this invention enables the preparation of carrier vehicles useful for the delivery of medically useful compositions for man and animals.
The finished products of this invention range from a red blood cell substitute (resuscitation fluid) to aqueous based formulations of water insoluble, water soluble and water sensitive drugs.
~ The fact that in the method of this inven-; 25 tion, aqueous formulations successfully incorporate and deliver water insoluble and water sensitive drugs is evidence that this invention constitutes a signifi-cant advance in the state of the art.
The aqueous based compositions of this inven-tion comprise one or more of a large variety of surface active agents, that is, molecules which are non toxic and endogenous or exogenous to the body and can include one or more monomeric, polymerized or polymerizable surface active agents, particularly a polymerized ~; 35 form of a protein such as albumin and/or a polymerized form of a phospholipid such as lecithin and may include one or more surface active agents either in polymeric ~.. . . .

-9- 132~2 or monomeric form, including lecithin, albumin, gela-tin, modified liquid gelatin, acacia gel and combina-tions thereof. Finished products of this invention may be administered by oral, parenteral, transdermal, transmucosal or inhalation routes, or by combinations of these routes.
Formulations prepared according to the method of this invention are stable, pharmacologically-active and will not precipitate in body tissue or fluid.
Parenteral drugs now prepared to an excessive pH can be reformulated using the method of this invention.
The resulting product will have improved bioavail-ability and absorption; said reformulation will reduce or eliminate pain and tissue damage associated with injection of drugs with an excessive pH. The physio-logically-active compounds, such as a drug, may be in a concentrated form, or may be dissolved or suspended in a carrier, e.g., a liquid carrier, such as an oil, glyceride, lipid, coacervate phase(s) or within a film carrier such as a liposome. In one emobdiment, a liposome is encapsulated in a coacervate-based matrix or coacervate phase and/or coacervate-based film to prevent the liposome from unravelling prematurely.
Either prompt or sustained release charac-teristics or mixtures thereof, can be manufactured by the method of the present invention. into the circu-latory system without being absorbed through the lining of the GI tract. The formulations are stable, pharma-~ cologically active and will not precipitate in body ; 30 tissue or fluid. The drug delivery formulations of this invention include emulsions, microemulsions and coacervate phase encased liposomes. In those delivery formulations which are preparéd to an excessive pH
and are administered parenterally, the herein disclosed formulations will improve dissolution, be free of the pharmacokinetic distortions associated with current drug vehicles and reduce or eliminate pain and tissue '-- :', ' - l o- 1 ~ 2 ~
damage. Use of this invention for orally administered drugs or other medically useful compositions signifi-cantly improves their bioavailability and absorption.
In brief, this invention comprises a coacervate system S containing at least one monomeric or polymerized sur-face active compound which can be processed to result in a composition including one or more physiologically-active compounds coated or encased with a coacervate phase film and may be in the form of a microemulsion to stabilize and improve the dosage forms specified above. The physiologically-active compounds, such as a drug, may be in a concentrated form, or may be dis-solved or suspended in a carrier, e.g., a liquid car-rier, such as an oil or glyceride, or within a film carrier such as a liposome. In one emobdiment, a liposome is encapsulated in a coacervate based matrix or coacervate phase and/or coacervate based film to prevent the liposome from unravelling.
The method of this invention enables the preparation of carrier vehicles useful for the delivery of medically useful compositions for man and animals.
Thus, the disclosed method can be used to produce a composition which comprises a red blood cell substitute (resuscitation fluid)~ if desired, by modifying the method, it will produce an effective plasma expander.
The method of the present invention using a polymerized or polymerizable surface active agent constitutes an improvement in incorporating ability ranging from two to six times greater than that of the inventor's pre-viously disclosed methods.
The delivery systems of this invention encom-pass emulsions, microemulsions, encapsulated liposomes, suRpensions, gels and microsuspensions. The size of the coacervate-based encapsulated particles which comprise the finished products of this invention extend from the nanogram range to about one micron when ad-ministered parenterally. Larger size particles may -11- 132~2 be made by the disclosed method if required. Filtering procedures may be used to insure appropriate pa~ticle size. This invention envisages compositions in which particles l micron or less are mixed with particles 2 microns or more.
In this invention, the pharmacologically-active component is bound to or embedded in the coacer-vate matrix comprising the pharmacologically-active compounds held in a coacervate matrix of the equili-brium water phase and/or the coacervate phase forminga particle; and the particle, including the pharmaco-logically-active component and equilibrium water and/or coacervate phase ~forming the coacervate matrix) is then encapsulated by a coacervate-based film. The coacervate-based film can contain one or more pharma-cologically-active component(s), and layered films can contain no, or different, pharmacologically-active components. The film can be prepared to any degree of structure (hardness) ranging from soft (semi-gel like) to rigid. The method provides for a mixture of particle sizes if desired, and for any degree of sur-face film hardness, any number of surface films with or without an active compound, or combinations thereof.
In accordance with one embodiment of the present invention, a perhalogenated compound and a two-phase aqueous coacervate system are combined to yield a useful composition that can be used to solu-bilize and stabilize physiologically-active compounds.
The resulting products can be administered orally or parenterally, preferably intravenously, to perform auch useful functions as acting as a barrier to food absorption to assist in weight reduction programs; as an oxygen-transporting contrast medium; and/or as a resuscitation fluid. The method and composition of the present invention also can be used to solubilize and stabilize non-polar physiologically-active pharma-ceutical compounds, such as drugs, enzymes, biologi--12- 132~2 cals, peptides, antimicrobials, anesthetic agents, or combinations thereof. Surprisingly and unexpectedly, according to the present invention, the anesthetic agents, including gases, liquids and liquifiable gases, can be incorporated into the composition of the present invention. In general, the composition and method of the present invention facilitates the manufacture of medically-useful products and facilitates the introduc-tion of these medically-useful products into the body.
In accordance with another embodiment, the physiologically-active compound is a heme, hemoprotein, and/or a heme-hemoprotein complex, such as stroma-free hemoglobin; polymerized hemoglobin: and/or pyri-doxilated, polymerized hemoglobin; and/or an oxygen solvent to augment the oxygen transport capability of the body, to treat for several of the anemias and/or to act as an oxygen-carrying plasma extender.
OBJECTS OF THE PRESENT INVENTION
Accordingly, an object of the present inven-tion is to provide a composition and a method of makingthe composition wherein one or more physiologically-active compounds are encapsulated by an aqueous coacer-vate-based film containing at least one monomeric or -polymerized surface active compound to provide unex-pected stability to the composition.
Another object of the present invention isto provide a composition and a method of making the composition wherein one or more physiologically-active compounds is dissolved or dispersed in a liquid carrier and the carrier and compound are encased in an aqueous coacervate-based matrix containing at least one mono-meric or polymerized surface active compound, the composition including an aqueous colloid-rich phase or an aqueous colloid-poor phase or a combination of both phases from a two-phase coacervate system.
Another object of the present invention is to provide a composition and a method of making the ", , .
' . ' ' ' ' "

.

-13- 13?,1~2 composition wherein one or more physiologically-active compounds is dissolved or dispersed in a liquid car-rier, such as a glyceride, and the carrier and compound are encased in an aqueous coacervate-based matrix containing at least one surface active compound includ-ing an aqueous colloid-rich phase or an aqueous col-loid-poor phase or a combination of both phases from a two-phas.e coacervate system, thereby preventing the compound from diffusing out of the composition prema-turely, and to prevent degradation of the compound by : body fluids.
Another object of the present invention isto provide a method of administering a physiologically-active compound to a mammal by oral ingestion, tissue lining absorption or parenteral administration wherein the composition includes one or more physiologically-active compounds in concentrated form or in a solid or liquid carrier, encased in an aqueous coacervate-based matrix containing at least one surface active compound, particularly a film containing an aqueous colloid-rich phase.
Still another object of the present inventiom i5 to provide a composition and a method of making the composition wherein previously encapsulated phy-siologically-active compounds, such as compounds encap-sulated in a liposome, are further stabilized by encap-sulation in an aqueous coacervate-based matrix contain-ing at least one surface active compound to prevent the compound from leaking by preventing the liposome from unravelling prematurely.
A further object of the present invention is to provide a composition and a method of making the composition wherein one or more physiologically-active compounds are encapsulated in an aqueous coacer-vate-based matrix containing at least one polymerized #Urface active compound, the matrix including a col-loid-riah or a colloid-poor phase, or a combination -14- 13~
of a colloid-rich and a colloid-poor phase to stabilize the physiologically-active compound and prevent the compound from prematurely leaking out of the coacer-vate-based film, and to prevent compound-degenerative materials, such as enzymes, or other digestive fluids, from reaching and degenerating the compound.
It is a further object of the present inven-tion to provide a non-toxic, two-phase aqueous coacer-vate-based composition, including a non-toxic perhalo-genated compound, such as a perhalogenated hydrocarbonand/or a perhalogenated amine, to solubilize and sta-bilize physiologically-active compounds, such as drugs, enzymes, biologicals, peptides, antimicrobials, anes-thetic agents, oxygen carriers, contrast media and mixtures thereof, and to facilitate the oral or paren-teral introduction o~ the physiologically-active com-pound into the body.
Another object of the present invention is to provide a composition and method of making the composition wherein one or more physiologically-active compounds are encapsulated by an aqueous coacervate-based matrix containing a polymer of lecithin to sub-stantially and unexpectedly increase the yield or amount of physiologically-active compound capable of being carried in the composition.
Another object of the present invention is to provide an aqueous coacervate-based composition, incorporating heme, hemoproteins, or a heme-hemo-protein complex, that can be used to increase the oxygen-transport and iron-transport capabilities of the body, to treat various anemias and/or to extend plasma volume.
Another object of the present invention is to provide a coacervate matrix enveloping one or more physiologically-active compounds wherein the coacervate matrix includes a plurality of surface active compounds ` -15- 13~
one of which is polymerized albumin or polymerized lecithin.
Another object of the present invention is to provide a composition and method of making the compound wherein a three-layer coacervate system is formed using a physiologically-acceptable alcohol, and the middle layer, comprising an aqueous colloid-rich phase, is separated from the other two layers and then formed into a second, two-phase coacervate system with one or both phases or layers suitable for encapsulating a physiologically-active compound for oral, tissue-absorptive, or parenteral administration.
Another object of the present invention is to provide a composition and a method of making the composition wherein one or more physiologically-active compounds is dissolved or dispersed in a liquid car-rier, such as a glyceride, and the carrier and compound are encased in an aqueous coacervate-based film includ-ing an aqueous colloid-rich phase or an aqueous col-loid-poor phase or a combination of both phases from a two-phase coacervate system, thereby preventing the compound from diffusing out of the composition prema-turely, and to prevent degradation of the compound by body fluids.
The above and other objects and advantages of the present invention will become apparent from the following detailed description of the preferred embodiments.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention provides for a stable drug delivery composition useful for the oral adminis-tration or tissue lining absorption of drugs and other medically useful compositions and for the stabiliza-tion, solubilization and delivery of pharmacologically active substances as parenterally administrable drugs at the pH of body tissue. The compositions of the present invention are derived from a non-toxic two--16- - 132~ ~2 phase aqueous coacervate system forming a matrix con-taining at least one polymerized surface active com-pound, one phase of which is colloid-rich, semipolar to nonpolar in character and capable of solubilizing oil-soluble and water-insoluble components; and the second phase of the coacervate composition is colloid-poor, semipolar to polar in character and capable of solubilizing water-soluble and, to a lesser degree, water-insoluble components. The polar phase of a coacervate composition is made of strong, dipolar from about O.lD to about 0.8D. The nonpolar phase is made up of molecules have little or no dipole charac-ter, generally in the range of 0 to O.lD. See Remington's Pharmaceutical Sciences, Mack Publishing Company, 1973, pp. 241-242. To a limited degree, however, the colloid-poor phase may be able to solubi-lize some apparently water-insoluble compounds, the colloid-rich phase being insoluble and in equilibrium with said colloid-poor phase. In this invention, a drug is incorporated in the coacervate phase based matrix and encapsulated comprises a medically useful, surprisingly stable composition suitable for oral, parenteral, transdermal, transmucosal or inhalation administration or combinations of such modes of ad-ministration.
As used in this invention the term, "trans-mucosal" means that a formulation of this invention is applied directly to any of the accessible mucosal membraneous tissues of the body. The term, "trans-dermal~ is used to mean a formulation applied directlyto the surface of the skin. ~Tissue absorptive~ in-clùdes both transdermal and transmucosal. The terms, ~oral~, ~parenteral~ and ninhalation" are used as per conventional definitions. In this invention, the oral route means that any oral dosage form can be accommodated, i.e., tablets, capsules, liquids, par-ticles, and the like.

-17~
The term "drug" is defined by the Federal Food, Drug and Cosmetic Act, and as used in the present disclosure, is "articles recognized in the official United States Pharmacopoeaia, offical Homeopathic S Pharma~oeaia, or official National Formulary or any supplement to any of them". Further clarification of this definition is supported by Remington's Pharmaceu-tical Sciences, which states "drug" to mean "any ar-ticle contained in the above-cited references which is used in the process of diagnosis, cure, treatment, mitigation or prevention of disease in man and animals~. Remington's Pharmaceutal Sciences, (Easton, Pa.: Mack Publishing Co., 1975), p. 1843. All drugs as encompassed by any of these definitions can be lS incorporated into the coacervate compositions of the present invention for oral or parenteral administration to mammals.
It is known that the active components of many parenteral drugs such as antibiotics, anesthetics, anticancer agents, hypertensive compounds, and the like, are insoluble or only slightly soluble at the pH of plasma or tissue fluids and as such, the proce-dures commonly employed to deal with this problem include use of the salt of the parent compound and/or use of propylene glycol and/or alcohol as a solubiliz-ing agent(s) for the drug. Physician's Desk Reference, ~oradell, N.J.: Medical Economic Co., 1986).
U.S. Pharmacopoeaia, indicates that of the injectable drugs used in the direct medical treatment of diseased states, approximately 200 are prepared from the salt of the parent compound and administered at a pH which differs significantly from that of body tissue. It follows fxom accepted pharmaceutic princi-ples that when a drug based upon the salt of a parent compound is injected, the intracellular and extracellu-lar water at the site of injection will buffer the drug sufficiently to alter its pH and cause a quantity ' of it to precipitate out of solution and into the injected site.
The following list illustrates the extensive use of the salt of the parent compound in injectable drugs as well as the frequency of an associated exces-sive pH. As is evident, virtually all classes of drugs are represented, and, in accordance with the principles of the present invention, are suitable for formulation in all embodiments of the coacervate com-positions of the present invention for oral or paren-teral administration or for tissue absorption.
DRUG pH
Acetazolamide, Sodim 9.0-10.0 Alphaprodine HCl 4.0-6.0 Amicocaproic Acid 6.0-7.6 : Aminosuppurate Sodium 6.7-7.6 Aminophylline 8.6-9.0 Aminotryptyline HCl 4.0-6.0 : Amobarbitol Sodium 9.6-10.4 Anileridine 2.5-3.0 Amphotericin B 7.2-8.0 Ampicillin 5.0-7.0 Anti coagulant Heparin Solution 5.0-7.0 Arginine HCl 5.0-6.5 Atropine Sulfate 3.0-6.5 Atrial Peptides Azathioprine Sodium 9.8-11.0 Benztropine Mesylate S.0-8.0 Betaine HCl 0.80-1.2 Betamathazone Sodium 8.0 Bethanecol Chloride 5.5-7.5 B~periden Lactate 4.8-5.8 Bleomycin Sulfate 4.5-6.0 Brompheniramine Maleate 5.8-7.0 Bupivacaine-Epinephrine Injection 3.3-8.5 Bupivacaine HCl 4.0-6.5 Butabartitol Sodium 10.0-11.2 . . .

.

... . . ............... .

. . .

-19- 1 3 2 1 r,~
Butorphanol Tartrate 3.0-5.5 Caffeine-Soidum Benzoate Injection 6.5-8.5 Calcium Glueptate Injection 5.6-7.0 Calcium Levulinate 6.0-8.0 5 Carboprost Tromethiamine Injection 7.0-8.0 Cefamandole Sodium 6.0-8.5 Cefamandole Nafate 6.0-8.0 Caphazolin Sodium 4.5-7.0 Cafataxime Sodium 4.5-65.
Ceftizoxime Sodium 4.5-6.5 Cephalothin Sodium 4.5-8.0 Caphaprin Sodium 6.5-8.0 ; Caphradine 8.0-9.6 Cafonocid Sodium -----Chloramphenicol 5.0-8.0 Chlordiazepoxide HCl 2.5-3.5 : Chloroprocaine HCl 2.7-4.0 ; Chlorothiazide Sodium 9.2-10.0 Chlorpromazine HCl 3.0-5.0 Cefoperazone Sodium 4.5-6.5 Chlorphenramine Maleate 4.0-5.2 Chloroquine HCl 5.5-6.5 Chlortetracycline NCl 2.3-3.3 Clorprothixene 4.0-5.0 Colchicine Desmopressin 6.0-7.0 Clindamycin Phosphate 5.5-7.7 Cimetadine Hydrochloride 4.0-6.0 ; Codeine Phosphate 3.0-6.0 . Corticotropin 2.5-6.0 Cyanocobalamin 4.5-7.0 ; ~ Cyclizine Lactate 3.2-4.7 Cyclophosphamide 3.9-6.7 Cyclosporine -----~:: Cysteine HCl 1.0-2.5 : 35 Chlorprothixene HCl 3.4 Dantrolene Sodium 9.5 Dacarbazine 3.0-4.0 ~ , .

~' ~

-20- ~~ 132~2 Cactinomycin 5.5-7,5 Daunorubicin HCl 4.5-6.5 Deslanoside 5.5-7.0 Desmopressin Acetate 3,0-5.0 Dexamethasone Sodium Phosphate 7.0-8.5 Diatrizoate Meglumine 6.0-7.7 Diatrizoate Sodium 4,5-7,5 Diazepam 6.2-6.9 Diazoxide 11.2-11.9 Dibucaine HCl 4,5-7,0 Dicyclomine HCl 5,0-5,5 Ditheylstilbesterol Disphosphate -----Digoxin _____ Dihydroergotamine Mesylate 3.2-4.0 Diphenhydramine HCl 4.0-6.5 Dimenhydrinate 6.4-7.2 Dobutamine HCl 2.5-5.5 Dopamine HCl 2.5-5.5 Dopamine HCl -Dextrose 3.0-5.0 Doxapram HCl 3.5-5.0 Doxorubicin HCl 3.8-6.5 : Droperidol 3.0-3.8 ; Dhphylline 5.0-8.0 Edetate Disodium 6.5-7.5 Emetine HCl 3.0-4.0 Ephedrine Sulfate 4.5-7.0 Epinephrine 2.5-5.0 Ergonovine Maleate 2.7-3.5 Ergotamine Tartrate 3.0-4.0 Erythromycin -----Erythromycin Ethylsuccinate 6.0-8.5 Seythromycin Gluceptate 6.0-8.0 Erythromycin Lactibionate 6.5-7.5 Estradiol Valerate -----; 35 Ethacrynate Sodium 6.3-7.7 : Ethylnorepinephrine HCl 2.5-5.0 Etidocaine HCl 11.0 :

.
. , .

, Fentanyl Citrate 4.0-7.5 Floxuridine 4.0-5,5 Fluorescein Sodium 8.0-9.0 Fluoracil 8.6-9.0 Fluphenazine Enanthate -----Fluphenazine HCl 4.8-5.2 Folic Acid 8.0-11.0 Furosemide 8.5-9.3 Fallamine Triethiodide 5.3-7.0 Gentamycin Sulfate 3.0-5.5 Glucagon 2.5-3.0 Glycopyrrolate 2.0-3.0 Haloperidol 3.0-3.8 Heparin-Calcium 5.0_7.5 Heparin-Sodium 5.0-7.5 Hetacillin-Potassium 7.0-9.0 Hexafluorenium Bromide 4.0-7.0 Histamine Phosphate 3.0-6.0 Hyaluranidase 6.4-7.4 Digitoxin -----Fructose 3.0-6.0 Hydralazine HCl 3.4-4.4 Hydrocortisone Sodium Phosphate 7.5-8.5 Hydrocortisone Sodium Succinate 7.0-8.0 Hydromorphone HCl 4.0-5.0 Hydoxocobalamin 3.5-5.0 : Hydroxyzine HCl 3.5-6.0 Hyoscyamine Sulfate 3.0-4.5 : Imipramlne HCl 4.0-5.0 Iophendylate 6.5-7.7 Iothalamate Sodium 6.5-7.7 Iron Dextran 5.2-6.5 Isobucaine HCl-Epinephrine -----Isoniazld 6.0-7.0 Isoproterenol HCl 3.5-4.5 Isoxsuprine HCl 4.9-6.0 Kanamycin Sulfate 3.5-5.0 -22- 1 3 ~ 2 Ketamine HCl 3.5-4.5 Leucovorin Calcium 6.5-8.5 Levallorphan Tartrate 4.0-4.5 Lidocaine HCl 5.0-7.0 Lidocaine HCl Dextrose 3.5-7.0 Lidocaine HCl-Epinephrine 3.3-5.5 Lidocaine HCl-Epinephrine Bitartrate 3.3-5.5 Lincomycin HCl 3.0-6.6 Magnesium Sulfate 5.5-7.0 Magnesium Chloride 1.5-2.5 Methlorethamine HCl 3.0-5.0 Menotropins 6.0-7.0 Meperidine HCl 3.5-6.0 -Mephentermine Sulfate 4.0-6.5 Mepivacaine HCl 4.5-6.8 Mepivacaine HCl-Levonordefrin 3.3-5.5 Meprylcaine HCl-Epinephrine 3.5-5.5 Mesoridazine Besylate 4.0-5.0 Metaraminol Bitartrate 3.2-4.5 Methadone HCl 3.0-6.5 Methicillin Sodium 5.0-7.s Methiodal Sodium 5.0-8.0 Methocarbamol 3.5-6.0 Methohexital Sodium 10.6-11.6 Methotrexate Sodium 8.0-9.0 Methotrimeprazine 3.0-5.0 Methoxamine HCl 3.0-5.0 Methscopolamine Bromide 4.5-6.0 : Methyldopate HCl 3.0-4.2 Methylergonovine Maleate 2.7-3.5 : Methylpredisolone Sodium Succinate 7.0-8.0 Metronidazone 4,5-7.0 Miconazole 3.7-5.7 Minocycline HCl 2.0-3.5 Mitomycin 6.0-8.0 Morphine Sulfate 2.5-6.0 Moxalactam Disodium 4.5-7.0 , -23- ~ 3 2 ~
Nafcillin Sodium 6.0-8.5 Naloxone HCl 3.0-4.5 Neostigmine Methylsulfate 5.-.6.5 Netilmicin Sulfate 3.5-6.0 Niacin 4.0-6.0 Niacinamide 5.0-7.0 Norepinephrine Bitartrate 3.0-4.5 Nylidrin HCl 4.5-6.5 Orphenadrine Citrate 5.0-6.0 Oxacillin Sodium 5.0-8.5 Oxymorphone HCl 2.7-4.5 Oxytetracycline 8.0-9.0 Oxytetracycline HCl 2.0-3.0 oxytocin 2.5-4.5 Papaverine HCl 3.0 or less Parathyroid 2.5-3.5 Penicillin G Potassium 6.5-8.5 Penicillin G Procaine 5.0-7.5 Penicillin G Sodium 6.5-7.5 Pentazocine Lactate 4.0-5.0 Phenobarbital Sodium 9.0-10.5 Perphenazine 4.2-5.6 Phenobarbital Sodium 9.0-10.5 Perphenazine 4.2-5.6 Phenobarbitol Sodium 9.2-10.2 Phentolamine Mesylate 4.5-6.5 Phenylephrine HCl 3.0-6.5 Phenytoin Soidum 10.0-12.3 Physopstigmine Salicylate 4.0-6.0 Phytonadione 3.5-7.0 Plicamycin 5.0-7.5 Posterior Pituitary 2.5-4.5 Potassium Acetate 5.5-8.0 Potassium Chloride 4.0-8.0 Prednisolone Sodium Phosphate 7.0-8.0 Prednisolone Sodium Succinate 5.7-8.0 Prilocaine HCl 5.0-7.0 Procainamide HCl 4.0-6.0 Procaine HCl 3.0-5.5 Procaine HCl-Epinephrine 3.0-5.5 Procaine-Phsnylephrine -----Hydrochlorides 3.0-5.5 Procaine and Tetracaine HCl and Levonodefrin 3.5-5.0 Prochlorperazine Edisylate 4.2-6.2 Promazine HCl 4.0-5.5 Promethazine HCl 4.0-5.5 Propiomazine HCl 4.7-5.3 Propoxycaine-Procaine HCl's-Norepinephrine Bitartrate 3.5-5.0 Propanolol HCl 2.8-4.0 Protein Hydrolysate 4.0-7.0 Pyridostigmine Bromide 4.5-5.5 Pyridoxine HCl 2.0-3.8 Quinidine Gluconate -----Reserpine 3.0-4.0 Riboflavin 4.5-7.0 Ritodrine HCl 4.8-5.5 Rolitetracycline 3.0-4.5 Scopolamine HCl 3.5-&.5 Secobarbital Sodium 9.0-10.5 Sisomycin Sulfate 2.5-5.5 Spectinomycin HCl 3.8-5.6 Streptomycin Sulfate 5.0-8.0 Succinylcholine Chloride 3.0-4.5 Sulfadizazine Sodium 8.5-10.5 Sulfixoxazole Diolamine 7.0-8.5 Superoxide Dismutase -----Terbutaline Sulfate 3.0-5.0 Testosterone Cypionate -----Testosterone Enanthate -----Tetracaine HCl 3.2-6.0 Tetracycline HCl 2.0-3.0 Tetracycline Phosphate Complex 2.0-3.0 -25- 13~J~
Thiamine HCl 2.5-4.5 Thimylal Sodium 10.7-11.5 Thiethylperazine Maleate 3.0-4.0 Thiopental Sodium 10.2-11.2 Thiothixene HCl 2.5-3.5 Tobramycin Sulfate 6.0-8.0 Tolazoline HCl 3.0-4.0 Tolbutaminde Sodium 8.0-9.0 Triamcinolane Diacetate 6.0 Tridihexethyl Chloride 5.0-7.0 Trifluoperazine HCl 4.0-5.0 Triflupromzine HCl 3.5-52.
Trimethaphan Camsylate 4.9-5.6 Trimethobenzamide HCl 4.8-5.2 Trimethoprimsulfamethoxazole 10.0 : Tromethamine 10.0-11.5 Tubocurarine Chloride 2.5-5.0 Vasopressin 2.5-4.5 Vincristine Sulfate 3.5-4.5 Vidarabine Concentrate 5.0-6.2 : Vinclastine Sulfate 3.5-5.0 Warfarin Sodium 7.2-8.3 Verapamil 4.1-6.0 It is to be understood that the above list of drugs is for purposes of illustration and is not provided as an all inclusive list of all the drugs which may be beneficially formulated or reformulated using the oral or parenteral drug, tissue absorptive, transmucosal, or inhalation delivery compositions of the present invention. Other physiologically-active compounds that can be encapsulated in the coacervate compositions of the present invention include biolo-: gically-active compounds, such as proteins, enzymes, anti-enzymes, peptides, catecholamines, anti-hista-mines, analgesics, and the like. For the purposes of the present invention "biological" is defined to mean any medically useful composition derived from a biolo-, -26- ~ 132~
gical source and/or a synthetic pharmacological equi-valent thereof such as insulin, heme, hemoglobin, and hormones; "enzyme~ or "enzyme systemn is defined to mean any protein or conjugated protein produced biolo-gically or synthetically and which functions as a biocatalyst; "peptide" refers to peptides and polypep-tides derived from either endogenous, exogenous, or synthetic sources and is used to mean polymers of amino acids linked together by an amide type linkage known as a peptide bond. Anti-enzymes are chemical or biological entities specific to a given enzyme which act to interfere with or terminate the biological activity of the enzyme. Other medically useful compo-sitions known to those skilled in the art, for example, gIobulin, one or more glycoproteins, such as erythro-poietin, also may be incorporated in the compositions of the present invention.
Drug compounds dissolved in any non-toxic, physiologically-acceptable solvent such as a glycol, for example, propylene glycol, and/or alcohol also may be used in the practice of this invention. The procedure and quantity of drug incorporated when using such compositions are any desired quantity, such as that described.
The following are examples of standard doses which can be incorporated into the coacervate-based matrix-enveloped compositions or products of this invention:
Cimetidine HCl 150 mg/ml Diazepam 5 mg/ml 5-Fluorouracil 500 mg/lOml Erythromycin Lactobionate l mg/ml Flosuridine 500 mg/5ml Amthoteracin D 0.l mg/ml Fluphenazine HCl 2.5 mg/ml Heparing Sodium 1,00-20,000 units/ml ...,...,, . ,. ,.: :

-27- ~-~ 13~ 2 Haloperidol lactate 5 mg/ml Insulin 40 units Ketamine HCl lO mg/ml Labeltol HCl 5 mg/ml Lipocaine HCl lO mg/ml Miconozole lO mg/ml Morphine Sulfate 0.5-l.O mg/ml Dropendal 2.5 mg/ml Imipramine HCl 25 mg/2ml Phenytoin lOO mg/ml Pentobartital Sodium 50 mg/ml Tetracycline HCl 250 mg/lOOml Thiopental Sodium 0.2 mg/2ml Verapamil HCl 2.5 mg/ml Vincristine Sulfate l.O mg/ml Fentanyl citrate 0.05 mg/ml Methylprednisolone Sodium Succinate 40 mg/ml Once the drug is solubilized in (held within the matrix of) the colloid-rich phase of the composi-tion of the present invention and adjustments are made to the pH, if necessary, e.g., to 7.3-7.4 by the addition, for example, of either hydrochloric acid or sodium bicarbonate, the preparation may be administered - 25 or stored in the standard or desired dose in appro-priate containers such as ampules, vials, and the like. Alternatively, following solubilization of the drug in the coacervate phase, the previously separated colloid-poor phase can be added and the resulting mixture emulsified using techniques known to produce microemulsions. Following adjustment of the pH to, for example, 7.3-7.4, by adding either ~Cl or sodium bicarbonate as required, the preparation is now ready for use or storage. In some instances, as noted pre-viously, the colloid-poor phase may be used to solu-bilize and prepare formulations of polar and semipolar drug compositions.

-28- ~3~ 2 Other medically useful compositions encom-passed by the definition of drugs herein are also delivered more effectively orally, parenterally or by other means of administration that eventuate in tissue absorption of the drug(s) by incorporation into the compositions of the present invention since such incor-poration improves such parameters as stability, solu-bility, delivery and the like. Other medically useful compounds capable of being incorporated in the composi-tions of all embodiments of the present inventioninclude vitamins, for example, vitamin B complex, vitamins A, D, E and K, vitamin sl2~ folic acid, and the like. Additionally, enzymes such as glucagon, lipase, a-amylase, superoxide dismutase, and the like, and nutrients such as fats, proteins, amino acids and carbohydrates may be incorporated into the drug deli-very compositions of the present invention. Nutrition-al formulations using the compositions of the present invention may include both water-soluble and water-insoluble compounds, for example, vitamins, polyun-saturated corn oil, soy oil, triglycerides, amino acids, soy protein isolate, soy lecithin, corn syrup, sucrose and other nutritional entities known to be useful when normal food intake is precluded or other-wise interfered with. Peptide and/or polypeptidecompositions, particularly dipeptides and tripeptides, also can be included in the compositions of the present invention. Additional active compounds includeable into the coacervate compositions of the present inven-tion, particularly for oral administration includeAzothioprine; Cyclosprine; Monensin; low molecular weight Heparin, Amrinone and other ionotropics; Super-oxide Dismutase; Protaglandins; Interferons; Urokinase;
hGH (human growth hormone); Aminoylycoside antibiotics;
Estrogens; Cephalosporins; Androgens; Anti-androgens;
Renin Inhibitors; Lipoxygenase Inhibitors; Hypothalmic and Pituitary Hormones; Cardiac Glyscosides; Anti--29- - 13~
inflamatory steroids; Non-steroid Inflamatory drugs;
Vancomycin; Tissue Plasminogen Activators; Enzymes such as adenosine deaminase; and blood factors, such as Factor VIII and Factor IX complex.
Compositions of one embodiment of the present invention comprise one or more non-toxic monomeric or polymeric surface active agents which may be derived from endogenous, exogenous or synthetic sources. For purposes of this invention, they may be selected from any of the classes of surfactants described by Zographi (Ref: Remington's Pharmaceutical Sciences, pp. 295-296, Mack Publishing Co. 1976). The polymers are obtained from the following monomers: anionic, cationic, amphoteric, and non-ionic surfactants. Sur face active agents in the anionic classification in-clude di-~2-ethylhexyl~ sodium sulfosuccinate; non-ionic compositions include polyethylene glycol (PEG) and polymerized esters; and amphoteric surface active agents include (1) compounds classified as simple, conjugated, derived, and secondary proteins such as the albumins; gelatins; modified fluid gelatins; lipo-proteins; alpha, beta and gamma globulins and glyco-proteins, and (2) compounds referred to as phospho-lipids. The amine salts and the quaternary ammonium salts within the cationic group also comprise useful surfactants. Other surfactant compounds useful to form coacervates in accordance with the principles of the present invention include compositions within the groups known as the polysaccarides and their deriva-tives, such as chitosan; dextran; the mucopolysac-carides; and the polysorbates and their derivatives.
Synthetic polymers that may also be used include com-positions such as polyethylene glycol and polypropylene glycol. Other suitable surface active agents that can be used to prepare coacervate compositions useful in accordance with the principles of the present inven-tion include pectin, glycoprotein, glycolipid, galac-tose, and modified fluid gelatin. Acceptable coacer-vate compositions can be made from single surface active agents listed above or through the use of appro-priate combinations thereof.
Compounds that are not intrinsically surface active may also be used to prepare coacervates provided they can be made surface active by chemical or other means. Thus, fatty acids are not considered to be surface active compounds; however, when they are re-~ acted with an alkaline chemical entity, the resulting reaction products will include one that has surface active properties. For instance, mixing stearic acid with sodium hydroxide will produce a salt of stearic acid that has surfactant characteristics.
Virtually all surfactants useful to this invention can by polymerized (e.g., modified fluid gelatin) and used in the method and compositions of the present invention.
As noted above, known synthetic polymers, e.g., polyethylene glycol dextran, a polysaccaride, and the like, may be used in this invention.
To achieve the full advantage of the present inventlon, the coacervate matrix includes at least one polymerized surfactant. The polymerized surfactant or a combination of polymerized and monomeric surfac-tants have produced delivery systems that are excep-tional in their ability to entrap hemoglobin and other pharmaceutical components.
Surfactants useful to this invention can be polymerized by using, as an example, any of the cus-tomary aldehydes ~e.g., gluteraldehyde) and following known procedures associated with the use of the alde-hydes to produce the polymer form.
:j To achieve the full advantage of the present invention, the combination of the surface active com-pounds include polymerized albumin and polymerized lecithin; polymerized albumin and monomeric lecithin;

;

-31- 13~1~k2 monomeric albumin and polymerized lecithin; casein and polymerized lecithin; gelatin and polymerized lecithin; pectin and polymerized albumin. It should be noted, however, that coacervate compositions useful S in accordance with the principles of the present inven-tion can be made from selected single surface active agents such as polymerized albumin or polymerized lecithin.
To achieve the full advantage of the present invention, one of the surface active agents should be a phospholipid, such as lecithin or polymerized leci-thin, in the composition of the present invention.
It may be derived from any suitable source. Egg leci-thin is preferred. Other phospholipids such as cephalin, isolecithin, sphingomyelin, phosphatidyl serine, phosphatidic acid, phosphatidyl inositol and phosphatidyl choline, and combinations thereof, may be used in place of or in addition to lecithin, parti-cularly where the other surfactant is polymerized albumin.
Further, to achieve the full advantage of the present invention, a suitable surface-active pro-tein, such as albumin or polymerized albumin, comprises another component of the compositions of the present invention. Albumin derived from any acceptable source, such as human, is acceptable. Other suitable surface active proteins include alpha-, beta- and gamma-globu-lins, gelatin, modified fluid gelatin, lipoproteins, polypeptides and mucopolysaccarides. While albumin is preferred, any suitable, non-toxic protein, i.e., simple, conjugated or derived proteins or mixtures thereof, including the globulins may be used in place of albumin. When globulin is used in the process described in this specification, the finished product not only comprises a coacervate but a composition in which the medical usefulness and the activity of the gamma globulin is prolonged.

-32- 1 3 2 ~ J
The use of an aqueous based coacervate com-position as the starting composition for the microemul-sions of the finished products of the present invention distinguishes the compositions of the disclosed inven-tion from known microemulsions that are comprised ofa lipid (liquid or solid) or oil phase and a water phase. It should be noted that stabilization of known microemulsions by encasing the microemulsions in a coacervate phase matrix and/or film, in accordance with the principles of the present invention, is an important feature of the present invention.
According to another embodiment of the method and composition of the present invention any non-toxic molecule capable of carrying, and releasing oxygen to the bloodstream of a patient, and/or an oxyqen solvent, preferably a molecule that contains iron, can be used as the physiologically-active com-ponent of the composition. Further, it has been found that, a heme, and/or a hemoprotein and/or a heme-hemoprotein complex can be used as the physiologically-active component. Since the heme, hemoprotein and heme-hemoprotein complexes contain iron, these pre-ferred compounds possess an important advantage because sources for the physiologically-active component in-clude endogenous, exogenous and synthetic composi-tions.
As used above and hereinafter, heme is de-fined to comprise the prosthetic group of hemoglobin.
However, according to the composition and method of the present invention, prosthetic groups of other compositions, such as myoglobins, catalases, cyto-chromes b and some peroxidases can also can be used to form the heme-hemoprotein complexes. The preferred heme molecule for use in the present invention is a complex of iron and protoporphyrin 9, type III. Simi-larly, hemoproteins that can be used above or in the heme-hemoprotein complex include hemoglobin, ovo-::

-33- ~ r'i~
globulin, ovocanalbumin, Cytochrome c, Cytochrome P450, polymerized hemoglobin, pyridoxilated-polymerized hemoglobin, ovomucin and lactalbumin. To achieve the full advantage of the present invention, when using a hemoprotein or the heme-hemoprotein complex combina-tion, hemoglobin of human, bovine, synthetic or genetic engineering sources, in stroma-free form, is utilized as the hemoprotein.
In accordance with an important embodiment of the present invention, all of the components of the present invention, and especially the heme, the hemoprotein and/or the heme-hemoprotein complex should be be pure and stable. Therefore, either prior to or after incorporating the heme, hemoprotein and/or heme-lS hemoprotein complex into the composition of the presentinvention, a solution of the heme, hemoprotein and/or the heme-hemoprotein complex is treated with a chemical agent that forms stable iron complexes with the heme, hemoprotein or heme-hemoprotein complex, such as a carbon monoxide or an inorganic cyanide, particularly cyanide salts or cyanide complexes, such as sodium cyanide hydrogen cyanide. The chemical agent can be removed readily from the heme, hemoprotein and/or heme-hemoprotein complex when an excess of oxygen is introducéd into the solution. For example, carbon monoxide is bubbled through the heme, hemoprotein and/heme-protein solution until all oxygen is removed from the solution. In a subsequent processing step, the complexed carbon monoxide is removed by introducing an excess of oxygen to the heme, hemoprotein and/or heme-hemoprotein complex. In accordance with a new and unexpected feature of the present invention, the intimate contact of the solution with carbon monoxide stabilizes the heme, hemoprotein and/or heme-hemo-protein complex during the manufacturing process,thereby preventing oxidation of the heme, hemoprotein and/or heme-hemoprotein complex.

-34- 132~2 Further, the composition prepared according to the method of the present invention provides iron that is absorbed into the body of humans and other mammals from the heme, hemoprotein and/or t~e heme-hemoprotein molecules as intact heme molecules. Thisabsorption duplicates the natural source and natural mode of iron absorption and, therefore, provides a significant imp~ovement over iron compounds now in commercial use. For example, usually the iron that is present in such commercial compositions first must be converted to ferrous iron in the stomach and duo-denum before any absorption occurs.
In accordance with an important feature of the present invention, the heme, hemoprotein and/or heme-hemoprotein complex present in the composition after oral administration is protected from degradation in the digestive tract by the coacervate phase of the coacervate system. A film of coacervate-phase water surrounds and completely coats each heme, hemoprotein and/or heme-hemoprotein complex to protect the heme, hemoprotein and/or heme-hemoprotein complex from gas-~;~ trointestinal degradation. The coacervate-phase water differs in physical structure from the bulk water which is present in the stomach, thereby slowing the as diffusion of digestive enzymes in the bulk water.
-~ Accordingly, the digestive enzymes are unable to pene-trate the film of coacervate-phase water that covers each heme, hemoprotein and/or heme-hemoprotein complex molecule, thereby reducing the rate of interaction of "
the enzymes with the heme, hemoprotein and/or heme-hemoprotein complex. This slow rate of interaction allows physiologically useful quantities of heme, hemoprotein and/or heme-hemoprotein complex to avoid degradation and, therefore, to pass through the walls of the small intestine and into the circulatory system I of the recipient. The protective feature afforded by ~ the coacervate phase also operates to protect the _35- 137,~
oxygen-carrying physiologically-active component(s) against degradation effects of pH, acid-base balance and other conditions and processes of the gastro-intestinal tract.
In accordance with another important embodi-ment of the present invention, liposomes and their contents are enveloped with a coacervate-based film -the film being derived from any of the two-phase liquid aqueous non-toxic coacervate compositions described herein. Liposomes of any acceptable composition and of any lamellar structure, i.e., unilamellar, multi-lamellar, or plurilamellar, or any combination may be used in accordance with the principles of this embodi-ment of the present invention. Further, the liposome may contain any of the following physiologically-active components: any oxygen carrying molecule or oxygen solvent(s), any drugs, hormones, biologicals, steroids, peptides, tissue plasminogen activators, enzymes, anti-enzymes and/or any other compositions or combinations thereof which are of biological or medical interest. Suitable oxygen solvents include perfluorocarbons; the coacervate phase of a lecithin-water coacervate solution; the coacervate phase of a lecithin-albumin-water solution, and the like. The source of the physiologically-active compound(s) can be either endogenous, exogenous or synthetic or any acceptable, non-toxic combination thereof.
The liposome embodiment of the present inven-tion comprises a liposome component, the pharmaceutic and/or pharmacologic entity(s), or combinations there-of, contained within the liposomes, and a coacervate-based matrix and/or film encapsulating the liposome component and its contents. In this embodiment of the present invention, liposomes containing the physio-logically-active molecule are mixed into a surfactant solution such as a solution of polymerized albumin.
To achieve the full advantage of this embodiment of -36- 132~/i2 the present invention, the surfactant (polymerized albumin~ solution also contains polymerized lecithin and is converted to a coacervate phase to form a coa-cervate matrix and/or film enveloping the liposome composition.
Further emulsification of this mixture pro-duces a composition enveloping the liposome in a coa-cervate-based matrix and/or film. The emulsified composition including the liposome enveloped by a coacervate-based matrix and/or film then is microemul-sified to produce a microemulsion having particles of 1 micron or less in size. As an option, microemul-sion(s) can be processed further to produce sustained release compositions; the methods include application ; }5 of heat; use of a cross-linking agent, or repeating specific process steps.
As a further option, the composition may be dried, such as by treatment with heat, or freeze dried to produce a lyophilized product, which can be produced to any desired particle size and reconstituted with any physiologically appropriate fluid. When reconsti- `
tuted, such compositions include a resuscitat on fluid and a delivery system to introduce compositions of biological or medical interest into the body.
The specific compositions of this invention can be administered either parenterally, transdermally, orally, absorbed through the tissue lining of other body sites, or via inhalation, or combinations thereof, as appropriate.
~hen the reconstituted composition is in-tended for intravenous use, isotonicity and pH should be adjusted by known procedures to normal body values before administration. A single layer of coacervate matrix and/or film encapsulates the composition. If desired, in accordance with a prefered method, the fini~hed product can be subjected to film encapsulation procedures repeatedly to produce concentric films of _37_ ~32~ 2 any desired thickness. Each film can contain no addi-tional physiologically-active component or each can contain a desired concentration of any physiologically-active component, same or different.
While it is preferred that the microparticles of the finished products of this invention be 1 micron or less, particularly when administered parenterally, there are conditions, such as for oral administration, when microparticles of this invention are 2 microns or more in size.
In accordance with one embodiment of the present invention, any appropriate non-toxic coacervate composition containing one or more polymerized surface active agents, particularly polymerized albumin and/or polymerized lecithin can be used in the manufacture of the drug delivery compositions of the present inven-tion. The coacervate-enveloped compositions of the present invention incorporate non-toxic endogenous or exogenous surface-active agents, derivatives thereof and/or combinations of surface-active agents or deri-vatives.
In the preferred formulation, polymerized albumin comprises one component. The lecithin that is used in this method may be monomeric or polymerized.
One method by which lecithin can be polymerized is as follows: Remove one or both of the fatty acids of lecithin by hydrolysis. This step results in a free hydroxyl group on each lecithin molecule. This in turn produces a lecithin composition that lends itself to polymerization by customary techniques.
To achieve the full advantage of the present invention, when polymerized albumin is used, the poly-merized albumin should contain from two to six albumin molecules. Longer molecule chains may be used but are not preferred. To achieve the full advantage of the present invention, the weight average molecular weight of the polymerized albumin, when used in this -38- 13~ 2 invention should range from about 200,000 to about 300,000, preferably from about 200,000 to about 280,000. Compositions of greater or lesser molecular weight may also be used. The albumin component can be derived from any acceptable, endogenous, exogenous, or synthetic source including genetically engineered sources. The lecithin may be derived from any suitable non-toxic source. In the practice of this invention, any acceptable phospholipid can be substituted for lecithin. In such case the phospholipid may be mono-meric or polymerized. To achieve the full advantage of the present invention, when polymerized lecithin used in the method and compositions of the present invention, the polymerized lecithin should contain three to four linked lecithin molecules and has a weight average molecular weight of about 1600 to about 3200, preferably about 2500. Shorter or longer chain phospholipids also may be used.
In preparing the red blood cell substitutes (resuscitation fluids), it is preferred that a reducing agent be added to the product in the process of manu-facture.
Depending upon the finished product to be produced, the pharmaceutically-active component may be an oxygen carrying molecule, an oxygen solvent molecule, hormone(s), water soluble drugs) water in-soluble drug(s), biological(s), a water sensitive drug~s), a peptide(s), an enzyme(s), and the like, either singly or in combination. The active component is incorporated in the composition during the manufac-turing steps in that quantity that will provide the desired clinical amount. Thus, for example, in the case of drugs, this will be the dose given in the Physician's Desk Reference plus five to fifteen per-cent. If desired, greater or lesser amounts of anygiven drug may be used to meet specific medical re-quirement3. In tùe case Oe the inclusion o~ hemoglo-_39~ r~rA!~
bin, the preferred quantity is that amount that will produce fourteen percent hemoglobin in the finished product. Greater or lesser quantities of hemoglobin may also be used depending upon the end use of the finished product. If desired, a sterol, such as cholesterol, and/or urea preferably about 0.1% to 3%
may be included in the composition to formulate red blood cell substitutes.
Any composition of this invention to be administered orally can be formulated to any dosage, e.g., capsules, tablets, syrups, emulsions, suspen-sions, microemulsions, and the like.
When preparing the intravenous red blood cell substitute of this invention, the basic method is followed. Additional steps are used, however, to adjust the pH, viscosity, and isotonicity of the pre-paration, when necessary, to approximate the values of whole human blood. In the method of this invention that prepares parenteral products, the p~ is adjusted to approximately 7.4. The oral drug compositions of this invention require no adjustment of pH, viscosity or isotonicity. pH adjustment, however, is preferred.
Manufacture of all preparations of this invention are preferably made under sterile conditions.
2S In accordance with another embodiment of the present invention, a composition comprising a non-toxic perhalogenated compound and a non-toxic two-phase coacervate aqueous system is utilized to prepare medically-useful products for oral or paren-teral introduction into the body. The coacervate-based composition can be used to solubilize and stabi-lize physiologically-active compounds, in order to facilitate delivery of medically-useful products, such as a resuscitation fluid, an oxygen-carrying contrast medium, or a pharmaceutical, into medical patients.

-40- 3 ? ~ ~3 ~ ~d The perhalogenated compounds that are useful in the present invention include organic compounds such as hydrocarbons, ethers and~or amines, having essentially all of the hydrogen atoms of the organic compound replaced by a halogen atom, such as fluorine, iodine, chlorine or bromine. of particular interest are the perfluorinated and perfluoroiodinated com-pounds, especially the perfluorohydrocarbons and per-fluoroamines, or hydrocarbons and amines having essen-tially all of the hydrogen atoms replaced by fluorineatoms.
To prepare the red blood cell substitute, the following method is used: to lO~ mls of a 30%
solution of monomeric lecithin, add lO gms of stroma-free hemoglobin and, if desired, also add 0.1% choles-terol. If cholesterol is used first it should be dissolved into the surfactant, e.g., lecithin, such as with the aid of a solvent, e.g., n-butyl alcohol.
The quantity of the hemoglobin component can vary from 1% w/v to 20% w/v. If desired, modified hemoglo-bin may be substituted in the same quantities for stroma-free hemoglobin. In addition, hemoglobin en-capsulated within liposomes may be substituted for the preferred stroma-free hemoglobin. It is preferred that a reducing agent and/or an antioxidant such as reduced nicatinamide adenine dinucleotide phosphate (NADPH), or reduced nicatinamide adenine dinucleotide phosphate (NADH), or glutathione, or dextrose, or ascorbic acid or other known non-toxic antioxidants be added as the next step. Appropriate combinations of reducing agents also may be used, if desired. If added, such compounds are added in such quantity as will prevent the oxidation of the hemoglobin component;
generally trace amounts up to about 3 molar percent based upon the molar amount of hemoglobin. To achieve the full advantage of the present invention, the reduc-ing agent should be included in an amount of from -41~
trace amounts to 6 millimoles per mole of hemoglobin.
Acceptable compositions may be prepared without the use of reducing agents.
Following this step add 20 gms of either S monomeric or polymerized albumin. The polymerized form is preferred. The resulting composition then is processed by means of a colloid mill and/or a micro-fluidizer for about 10 minutes. During this processing step add a polymerization initiator, e.g., a solution of 1-ethyl-3-dimethyl-aminopropyl-carbodiimide of about 10% added during colloid milling and/or micro-fluidizing for in-situ polymerization of the albumin during processing of the composition. The quantity of polymerization initiator may range from about 0.1%
to about 20% based on the total wei~ht of the composi-tion. Following this processing step the product is stored from about 4 to about 12 hours at a temperature that may range from about 4 C to about 10 C. The internal phase (particles) are separated from the aqueous system by known filtering or separation means and washed with sterile saline solution. The particles then are dispersed in physiological saline solution.
The p~ of the preparation is adjusted, if necessary, to approximate that of whole human blood.
Addition of HCl or NaO~ may be used for this purpose.
Isotonicity of the product is adjusted, if necessary, to approximate that of whole human blood. This may be accomplished by the addition of appropriate amounts of any of the following: electrolytes present in human plasma, normal physiological saline solution, Ringer's solution, or any other suitable composition.
Next, adjust the viscosity of the product so that it approximates the viscosity of whole human blood, for example, by the addition of water to de-crease the viscosity, or by adding any non-toxic, physiologically-acceptable hydrophillic colloid, such as albumin or pectin, to increase the viscosity. On completion of this step the product comprises a micro-emulsion that consists of microencapsulated particles containing the hemoglobin component. It should be emphasized that this method encapsulates hemoglobin more efficiently than that of the inventor's previously disclosed encapsulating techniques.
At this stage of manufacture the product may be used as a red blood cell substitute (resuscita-tion fluid) provided that it is first filtered to remove all extraneous matter and all particles that exceed l micron in size in any dimension.
It is preferred, however, that the filtered product be processed further using either a chemical process based on a crosslinking agent, such as gluter-aldehyde, or a physical processing step such as heat.The heating step is preferred and consists of heating the preparation for about 2 minutes at a temperature that may range from about 50 C to about 70~ C. The duration of the heatiny step may be more than 2 minutes or less than 2 minutes depending upon the desired degee of particle(s) surface film structuring. While temperatures less than 50 degrees Centigrade are fea-sible for this purpose, they are not preferred. A
combination of crosslinking and heating for film har-dening also can be used.
Depending upon the time and temperatureused in the the heating step, the encapsulating surface film produced by this step will range from gel-like to rigid in character. Following this step the result-ing composition is filtered to remove all extraneousmatter and any microencapsulated particles that exceed l micron in size in any dimension. The finished pro-duct of this invention can consist of particles with a single degree of surface film hardness or, alterna-tively, can consist of particles of mixed surfacefilm hardnesses. The desired quantity of said parti-cles can be added to any appropriate physiological -43- 1 ~ ?, ~
fluid. As such it will then comprise a product suit-able for intravenous administration as a red blood cell substitute (resuscitation fluid). If desired, the microencapsulated particles may be used in much the same manner as packed red blood cells. If desired, the product may be lyophilized or otherwise dried using conventional techniques. The dried composition may be reconstituted as needed using an appropriate physiological fluid either as a blood substitute or as a perfusion fluid.
This invention provides for several alterna-tive methods of preparing an intravenous red blood cell substitute. One alternative consists of the following steps: prepare polymerized albumin by adding 1 ethyl-3-dimethyl-aminopropyl-carbodiimide (EDC) to a 10% solution of monomeric albumin in an amount suf-ficient to produce a concentration of 5.0% w/v EDC in the product. Process in a colloid mill and/or a micro-fluidizer for about 10 minutes. Next, store the pro-duct at about 4 C for about 10 hours. Next, mix a10% w/v solution of pyridoxilated polymerized hemoglo-bin in an amount sufficient to achieve a hemoglobin concentration of about 10% by weight of the surfactant-water composition and, if desired, add about 2 milli-moles of NADPH into the product and process in a col-loid mill and/or a microfluidizer for about 10 minutes;
following this step, mix a solution of polymerized lecithin into the solution in an amount sufficient to provide a polymerized lecithin concentration of about 8% by weight of the solution and process again in a colloid mill and/or a microfluidizer for about 10 minutes. Next, adjust the pH of the product to that of whole blood using HCl or NaOH as necessary. Follow-ing this step, adjust the isotonicity using plasma electrolytes in such concentration as will give the product the isotonicity of whole human blood. Adjust the viscosity as the next step so that the viscosity -44~ 2 approximates that of whole blood. At this stage of manufacture the product may be used as a red blood cell substitute (resuscitation fluid) provided that it is first filtered to remove all extraneous matter and all particles that exceed l micron in size in any dimension. It is preferred, however, that the filtered product be processed further using either a chemical process based on a non-toxic crosslinking agent, such as gluteraldehyde, or a physical processing step, such as heat. The heating step is preferred and con-sists of heating the preparation for about 2 minutes at a temperature that may range from about 50 C to about 70 C producing a film that can range from gel-like to rigid in character. Following this step, the resulting composition is ~iltered to remove all ex-traneous matter and any microencapsulated particles that exceed l micron in size in any dimension. The finished product of this invention can consist of particles with a minimal degree of surface film hard-ness or, alternatively, it can consist of particlesof mixed surface film hardnesses. The desired quantity of said particles can be added to any appropriate physiological fluid. As such it will then comprise a product suitable for intravenous administration as a red blood cell substitute (resuscitation fluid). If desired, the microencapsulated particles may be used in much the same manner as packed red blood cells.
If desired, the product may be lyophilized or otherwise dried and reconstituted with any appropriate physio-logical fluid.
In accordance with another important embodi-ment of the present invention, the coacervate-based, hemoglobin-containing compositions of the present invention can be used as a perfusion fluid for prevent-ing degeneration of an organ or tissue used for trans-plantation or replacement of the organ or tissue for a mammal. When used as a perfusion fluid, the hemoglo--45- 1 3 ~
bin-containing active compound, e.g., hemoglobin, stroma-free hemoglobin, pyridoxilated polymerized hemoglobin and/or modified hemoglobin, should be pre-sent in the coacervate composition in an amount of 0.5% to 30% by weight of the coacervate composition, preferably l~ to 20% by weight of the coacervate com-position. The coacervate-based perfusion fluids of the present invention are useful with or without a hemoglobin component and can be used in ambient air or may be oxygenated for additional oxygen transfer to the tissue or organs. The coacervate-based perfu-sion fluid is capable of maintaining tissue and organs viable for up to at least 15 days and sometimes up to 30 days whereas prior art perfusion fluids generally are capable of sustaining tissue viability for only about 8 to 10 hours.
Another alternative coacervate-based intra-venous red blood cell substitute using the methods of this invention comprise the following steps:
Mix 10~ w/v of stroma-free hemoglobin into a solution of polymerized lecithin of about 20~ concen-tration. Process the product in a colloid mill and/or a microfluidizer for about 2 minutes. Mix ascorbic acid of at least 0.1 gm per 100 ml of solution and an amount equal to 10~ w/v (100 units/cc. in the finished product) of polymerized albumin into the product and process the resulting product in a colloid mill and/or a microfluidizer for about 5 minutes. Next, store the product for about 10 hours at 4 C. Adjust the pH of the preparation after the period of storage to about 7.4 using HCl or NaOH as necessary. Following this step, add electrolytes present in human plasma in such amount as will give the product the isotonicity of whole human blood. Next, adjust the viscosity of the product so that it approximates the viscosity of whole human blood. On completion of this step, the product comprises a microemulsion that consists of ,:
,,,,,,, --46- 1 3 ~
microencapsulated particles containing the hemoglobin component. At this stage of manufacture the product may be used as a red blood cell substitute (resuscita-tion fluid) provided that it is first filtered to S remove all extraneous matter and all particles that exceed 1 micron in size in any dimension. It is pre-ferred, however, that the filtered product be heated for about 2 minutes at about 70 C. The product then is filtered to remove all extraneous matter and all microencapsulated particles which exceed 1 micron in any single dimension. After this step, the product may be used as an intravenous blood substitute or stored preferably at 4 C until needed.
In accordance with another important embodi-ment of the present invention, the coacervate-based, hemoglobin-containing compositions of the present invention can be used as a perfusion fluid for prevent-ing degeneration of an organ or tissue used for trans-plantation or replacement of the organ or tissue for a mammal. When used as a perfusion fluid, the hemo-globin-containing active compound, e.g., hemoglobin, stroma-free hemoglobin, pyridoxilated polymerized hemoglobin and/or modified hemoglobin, should be pre-sent in the coacervate composition in an amount of 0.5% to 30~ by weight of the coacervate composition, preferably 1% to 20~ by weight of the coacervate com-position. The coacervate-based perfusion fluid is capable of maintaining tissue and organs viable for up to at least 15 days and sometimes up to 30 days whereas prior art perfusion fluids generally are cap-able of sustaining tissue viability for only about 8 to 10 hours.
While the processes described above use hemoglobin as the active component and yield intra-venous red blood cell substitutes, this invention, asnoted previously, enables the use of any medically useful composition as the active component to prepare --4 7-- ~ t` fi ~i, compositions that can be administered via parenteral, oral, transdermal, transmucosal and inhalation routes.
Also, while the size of the particles of the injectable or parenteral red blood cell substitute should be l micron or less in size in any diameter, there are other embodiments of this invention in which the particle size comprising the composition can be more than l micron and further, in specific instances of this invention desirable compositions will be com-prised of a combination(s) of particles with differing sizes; i.e., a given percentage of the particles will be l micron or less in size and the remaining percent-age of particles will be 2 microns or more. Percent-ages and particle siæes will vary depending upon the spe~ific formulation and ~he specific drug or combina-tion of drugs used in the formulation.
In ~he preferred embodiment of an orally administered composition of this invention, the follow-ing process is used.
More specifically, warm a mixture of 7.5 gms of monoglyceride and 7.5 gms of diglyceride at from 65-70~ C until a clear solution of the mixture is produced.
Unequal proportions of these glycerides may be used, but are not preferred. Equal or unequal proportions of mono-, di- and triglycerides also may be used. However, this mixture is also not preferred.
When the warming step is completed the pharmaceutical component is mixed into the solution. The product of this step is subjected to a spray drying step while the product is gradually cooled. The product resulting from this step will be a powder comprising particles containing the pharmaceutical component.
The next step is designed to coat the par-ticles with a coacervate film. The procedure is as follows. Make a suspension of the powder referred to above in lO0 mls of water containing lO gms of poly--48- ~ 32~r~,~
merized albumin and 10 gms of monomeric lecithin.
Stir the composition for about two minutes. Add an appropriate alcohol dropwise, n-butyl alcohol is pre-ferred, until a coacervate forms and coats the par-S ticles with a coacervate film, stirring during the addition of alcohol and afterward to insure that coa-cervate encapsulation of the particles continues for from 1/2 to 3 hours. The product then is stored for from 12 to 24 hours at about 4 C. The composition can be further microfluidized after encapsulation to further reduce the particle size, regardless of the number of films applied over the particles.
Following the storage step, the particles are separated from its liquid vehicle by filtration or other known appropriate methods and dried using any of the conventional drying techniques. This method yields a finished oral medically useful product com-prised of a coacervate encapsulated pharmaceutically-active component.
If desired, the product referred to above can be processed further to produce a sustained release composition. This may be accomplished by any of sever-al methods including application of heat, use of a cross-linking agent, such as gluteraldehyde, or cover-ing the encapsulated product with one or more addi-tional layers of coacervate film. The additional layer(s) of coacervate film is preferred. The addi-tional layers can contain the same or different physio-logically-active compound in a concentra~ion of about 0.5% to about 50% based on the weight of the film, or may contain no additional physiologically-active com-ponent.
The procedure is as follows. Make a suspen-sion of the powder referred to above in 100 mls of water containing 10 gms of polymerized albumin and 10 gms of monomeric lecithin. Stir the composition for about 2 minutes. Add n-butyl alcohol dropwise until -49- ~ ~3~
a coacervate forms and coats the particles with a coacervate film, stirring during the addition of al-cohol and afterward to insure that caacervate-encap-sulation of the particles continues for from 1/2 to 3 hours. The product is then stored for from 12 to 24 hours at about 4 C.
Following the storage step, the particles are separated from their liquid vehicle by filtration, sieve or other known appropriate methods and washed and dried following any of the conventional drying techniques. Repeating this procedure will add an additional coacervate layer ~film) containing no addi-tional physiologically-active compound to the composi-tion. The additional layers (films) can include one or more pharmaceutically-active component together with the coacervate-based encapsulating film if adde~
to the coacervate composition, or may contain no addi-tional physiologically-active component, as desired.
This process may be repeated as often as required to produce one or more additional layers ~films) with corresponding sustained release effects and/or contain-ing any combination of active components. The parti-cular active ingredient(s) and quantities of the active ingredient(s) within each layer can be varied to meet dosage requirements.
If desired, the structure of the surface of any of the layers referred to above can be hardened by applying heat to the product at a temperature and duration that will not adversely effect the activity of the pharmaceutic component. Any non toxic denatur-ing or polymerizing agent can be used in place of heat. If the heating step is incorporated in the de8cribed method, the release of the active component will be extended over a greater time period. It should be noted that in preparing the sustained release pro-; ducts of this invention, any single procedure or com-bination of procedures may be used provided that such .,. , .. --.. ....

--s o ~ cj i r~
procedure does not compromise the activity of the pharmaceutical component.
The particle size of the oral form of the composition of this invention can be any size suitable for the optimal delivery of the incorporated pharma-ceutical component~s). The herein described oral formulation can be used in any of the known dosage forms such as tablets, capsules, syrups, caplets, powders, and the like.
An alternative formulation for an orally administered medical composition uses the following method. In this method, any non polar volatile, or-ganic solvent may be used. In this instance carbon tetrachloride is the solvent. ~owever, it must be emphasized that in the use of such solvents, all traces of this component must be removed in one of the manu-facturing steps before proceeding to produce the finished product. The process is as follows: mix lO
gms of lecithin in lOcc of carbon tetrachloride: this will result in a clear solution. Add the pharmaceuti-cal component into the solution (e.g., 5 gms of erythromycin) and mix thoroughly. Using any appro-priate method, i.e., spray drying, distillation or the like, process the product to remove the carbon tetrachloride. Spray drying is preferred. This pro-cess will yield powder-like particles comprised of lecithin and the pharmaceutical component encased in the lecithin matrix.
The next step is designed to coat the par-ticles with a coacervate film. The procedure is asfollows. Make a suspension of the powder referred to above in lO0 mls of water containing lO gms of poly-merized albumin and lO gms of monomeric lecithin.
Stir the composition for about two minutes. Add an appropriate alcohol dropwise, n-butyl alcohol is pre-ferred until a coacervate forms and coats the particles with a coacervate film, stirring during the addition -51- 13~
of alcohol and afterward to insure that coacervate encapsulation of the particles continues for from 1/2 to 3 hours. If desired, the same or a different phar-macologically-active component can be added to the S albumin-lecithin solution for incorporation into each additional film layer. The product then is stored for from 12 to 24 hours at about 4 C.
Following the storage step, the particles are separated from its liquid vehicle by filtration or other appropriate means and dried using any conven-tional method. This yields a finished oral product of the pharmaceutically-active component coated with a coacervate-based film. The product can be used to prepare capsules or reconstituted with an appropriate liquid(s), e.g., syrup, to produce a product with the desired clinical dose.
If desired, the product referred to above can be processed further to produce a sustained release composition. This may be accomplished by any of sever-al methods including application of heat, use of across-linking agent such as gluteraldehyde, or covering the encapsulated product with one or more additional layers of coacervate film. The additional layer of film is preferred, and any of the additional layers can be hardened for sustained release. It is preferred that the final layer not be hardened for prompt release of any active component contained therein.
The procedure is as follows. Make a suspen-sion of the powder referred to above in 100 mls of water containing 10 gms of polymerized albumin and 10 gms of monomeric lecithin with or without 0.5% to 50%
w/v of any physiologically-active compound. Stir the composition for about 2 minutes. Add n-butyl alcohol dropwise until a coacervate forms and coats the par-ticles with a coacervate film, stirring during the addition of alcohol and afterward to insure that coa-cervate-encapsulation of the particles continues for _ ,., ", . .. .. . .

- 5 2~ h ~
from 1/2 to 3 hours. The product is then stored for from 12 to 24 hours at about 4 C. Longer contact of the particles with the coacervate, while stirring, provides thicker films for control of film thickness and control of the amount of the active compound, if any, contained therein.
Following the storage step, the particles are separated from the liquid vehicle by filtration, sieve or other known appropriate methods and dried using any of the conventional drying techniques. This procedure will add a coacervate layer (film) to the composition; said layer (film) comprising the pharma-ceutically-active component, if any, and the coacer-vate-based encapsulating film. This process may be lS repeated as often as required to produce one or more additional layers (films) with corresponding sustained release effects. The quantities of the active ingre-dient(s) within each layer can be varied to meet dosage requirements.
If desired, the structure of the surface of any of the layers referred to above can be hardened by applying heat to the product at a temperature and duration that will not adversely effect the activity of the pharmaceutic component. Any non toxic denatur-ing or polymerizing agent can be used in place of heat. If the heating step is incorporated in the described method, the release of the active component will be extended over a greater time period. It should be noted that in preparing the sustained release pro-ducts of this invention, any single procedure or com-bination of procedures may be used provided that such procedure does not compromise the activity of the pharmaceutical component.
The particle size of the oral form of this alternative can be any size suitable for the optimal delivery of the incorporated pharmaceutical compon-ent(s). The herein described oral formulation can be - -53~
used in any of the known dosage forms such as tablets, capsules, syrups, caplets, powders, and the like.
It is preferred that both the matrix contain-ing the physiologically-active component~s) and the S film that encapsulates it be coacervate derived or based. However, if desired, the matrix and/or film may be comprised of a non-coacervate composition.
For example, the film may be comprised of such materials as glycerides, carnuba wax or sugar, and the like. If a sugar coating is to encapsulate the matrix, the particles comprised principally of matrix containing the active compound are dispersed in thick sugar syrup and the composition is mixed rigorously for from 30 seconds to 5 minutes or more depending on lS the desired film thickness~ Following this step, the particles are separated from the vehicle by filtering if a consistent size particle is desired or centrifuged or by any other acceptable conventional process. If a non-coacervate based matrix is desired, the following method is used (See method for inhalation composition.) The film in such case will be coacervate based.
As noted previously, this invention provides for modifications of the basic formulation. Such modifications produce medically useful compositions which can be used either transdermally or transmucos-ally. These formulations involve processing the pre-ferred oral composition to produce a gel.
When applied transmucosally, (i.e., intra-nasally or rectally), the gel composition of this ~ 30 invention adsorbs onto the mucous or rectal membranes ; and is absorbed therein through the mucosal tissue to the blood stream. The active component is released from the gel and is absorbed by the membranes, passing into the blood stream by way of the capillaries. The gel composition can be prepared in forms that provide for immediate release, sustained release or any com-bination thereof. The quantity of drug incorporated ,' ~ .

-54- 1~?,~ r ~
can be varied according to medical requirements. Only those active components which are intrinsically irri-tating to the nasal or rectal membranes are not desir-able for incorporation in the gel.
S Preparation of the gel can be accomplished, as an example, by mixing additional albumin, or pectin or combinations thereof into the oral formulations.
Accordingly, hydrocolloids, particularly bioadhesive hydrocolloids, such as albumin and pectin, are added after the oral formulation has been completed to for-mulate the gel.
The gel composition can incorporate non polar drugs. These may be further subclassified as drugs or other physiologically-active compound(s) which are heat sensitive and drugs or other physio-logically-active compound(s) which are heat stable.
Thus, erythromycin is an example of a heat stable composition; insulin is regarded as a heat sensitive composition. In the process of this invention, heat stable drug preparations can be "fixed", i.e., the encapsulating film can be hardened or structured in the manner described. On the other hand, heat sensi-tive drug preparations can be structured by the appli-cation of physical techniques such as radiation or physicochemical means, such as n-butyl alcohol which form a coacervate and then an encapsulating film of the composition.
The process to prepare the gel is based on any of the oral preparations described above. It is preferred however, to use the above-described example method incorporating the mono and di glyceride compon-ents. More specifically, warm a mixture of 7.5 gms of monoglyceride and 7.5 gms of diglyceride until a clear solution of the mixture is produced.
Unequal proportions of these glycerides may be used, but are not preferred. Equal or unequal proportions of mono-, di- and triglycerides also may _55_ 1 3h~
be used. However, this mixture is also not preferred.
When the warming step is completed the pharmaceutical component is mixed into the solution. The solution then is subjected to a spray drying step while the product is gradually cooled. The product resulting from this step will be a powder comprising particles containing the pharmaceutical component.
The next step is designed to coat the par-ticles with a coacervate film. The procedure is as follows. Make a suspension of the powder referred to above in l00 mls of water containing l0 gms of poly-merized albumin and l0 gms of monomeric lecithin.
~tir the composition for about two minutes. Add an appropriate alcohol dropwise, n-butyl alcohol is pre-ferred, until a coacervate forms and coats the parti-cles with a coacervate film, stirring during the addi-tion of alcohol and afterward to insure that coacervate encapsulation of the particles continues for from l/2 to 3 hours. The product is then stored for from 12 to 24 hours at about 4 C.
Following this step, the composition is processed through centrifugation, sieving or other appropriate separatory techniques to separate the coacervate drug particles from its vehicle and to retain particles having a gel-like surface. Following this step, a bioadhesive hydrocolloid, such as albumin or pectin or any appropriate combination thereof, is mixed into the composition. The quantity of albumin that may be used ranges from about 2% w/v to about 20% w/v; the range of pectin that may be used also ranges from about 2% w/v to about 20% w/v. 10% w/v of pectin is preferred. The pH of the preparation is adjusted to about 7.4 by the addition of HCl or NaOH, as required.
In the case of heat unstable drugs, and the like, the process described above is modified. Follow-ing the coating step the composition is stored at -56- ~ r ~
room temperature for about 24 to 72 hours. After this period, the composition may be used or the compo-sition may be heated at from 40 to 50 C until the particles assume a soft gel-like character. It is preferred that following the coating steps the prepara-tion can be processed by the dropwise addition of a suitable protein denatuxing agent, such as ethyl al-cohol, n-butyl alcohol, isopropyl alcohol, and the like, until the structure of the interfaces of the particles range from soft gel-like to semi-solid. N-butyl alcohol is preferred.
If desired, a sustained release effect for this composition is achieved by subjecting portions of the product to heat, a cross-linking agent or radia-lS tion or combinations thereof. Heat is pre~erred.The following procedure is provided as an example.
20% of the composition is not heat treated. 20% is heated at 70 C for 40 seconds; 20~ is heated at 65 C Eor 60 seconds and the remaining 20~ is heated at 60 C for 90 seconds. The point to be made is that the exact combination of heat and time depends upon the specific drug being used and the desired schedule of drug release.
Microparticles comprising the transmucosal products can range from less than 1 micron to 6 microns or more in size. Particles less than 1 micron in size are preferred. The quantity of drug or other active agent to be incorporated into the composition is determined by medical considerations and can range from 1/2 of the convention oral or intravenous dose to four times the conventional dose.
After the composition is produced, e.g., normal or sustained release or combinations of normal and sustained release, the composition is placed in any dosage form suitable for nasal or rectal adminis-tration.

-57- - ~2~
The process used to produce the transmucosal gel is used to produce the transdermal gel except that the adjustment of the pH is not required. In this embodiment, the drug or combination of drugs is S sequestered or otherwise incorporated in a coacervate-based composition comprised of microencapsulated par-ticles which range from semi-liquid to gel-like in structure. The composition~s) may be applied directly to the skin in such forms as ointments or gels and incorporated in a cellulose based patch or a suitable container. In the preferred mode, the composition is placed in a container and used in conjunction with an appropriate sonifier. By this technology an unexpected degree of drug absorption by the skin is achieved.
lS Moreover, the transdermal gel and sonifier permits any scheduled administration or emergency administra-tion as required.
While transdermal methods of drug administra-tion are known, the literature does not reveal a tech-nique in which a coacervate-based microencapsulated composition is used in conjunction with a sonifier.
In this embodiment of the invention, use of a sonifier produces a local cavitational effect in the skin and in underlying tissue fluids, the net effect of which is to make the skin more permeable to the drug(s) being administered and to make the drug more available to the underlying tissues, including the capillaries and microcirculation. The cavitational effect is induced when sonification is applied and is ended when sonification is terminated. The application of the sonifier permits intermittent increases in skin permeability to administered drugs as required.
In the preferred practice of this invention, the finished product, e.g., the coacervate-based gel containing the medication required for either single or multiple doses, is placed in a suitable, leak proof container approximately the size of a wrist watch.

,,;

The bottom of the container should be made of a semi-porous or microporous support layer, e.g., a cellulose layer. The sides and top of the container should be made of plastic or other suitable non toxic material.
The top of the container should have an opening large enough to contain the head of a hand held sonifier such as NOVOPHON (manufacturer: Elredge Resources).
Any suitable sonifier presently used for physical therapy can be used in accordance with this embodiment of the present invention. The container should be constructed such that a thin layer of either aluminum foil or plastic or other composition suitable to trans-mit the sonifier effects to the medication and the skin is placed between the medication and the sonifier lS head. The medication is administered transdermally, as required by placing the head of the sonifier in the container and activating the sonifier for the time necessary to administer the prescribed dose of medication.
Presently available transdermal patches are characterized by a continuous straight line release of the drug. This has been shown to be problematic with drugs such as nitroglycerin. In addition, such , release is inconsistent with the body's normal release of hormones, enzymes and the like. Thus, by way of illustration,~ the body normally secretes very small quantities of insulin throughout the day. Upon inges-tion of food, however, a surge of insulin is released.
This invention permits a virtual duplication of such release phenomena not only for endogenous compositions but for medically useful exogenous compounds as well.
In addition, this invention enables transdermal ad-~- ministration of medication according to any medically -~ prescribed schedule.
This invention differs importantly from Zeffarone (U.S. patent No. 4,557,723) in that in his techniques a rate controlling membrane is used and is .... .

. .,,, . : . .

~59~ - ~ ~2~2 limited to drugs which show natural diffusive flux.
No such features and limitations are present in this embodiment of the present invention. Ariura (U.S.
patent No. 4,474,570) uses iontophoresis as the driv-ing force. However, the Ariura device produces anunacceptable degree of heat in its operation. The present invention does not generate unacceptable heat;
its driving force not only differs but its effect upon the skin differs from that of iontophoresis.
The U.S. patent of Sibalis (4,557,723) describes an electrophoretic technology but also identifies the problems with known transdermal delivery devices.
The Sibalis technology is fundamentally unrelated to the transdermal-sonifier embodiment of the present invention. Sibalis relies upon battery supplied elec-trical current which battery must be changed according to different flow requirements. Sibalis simply refers to a medicament. In the Ecanow patent, medications are encapsulated in coacervate-based films. The herein described use of localized sound waves as opposed to electrical current is an unobvious modification in that in the herein disclosed use, sound waves produce an effect on the skin and tissue fluids of the site that renders the site more permeable to drugs within the coacervate compositions. Sibalis and others who have described transdermal inventions do not disclose such properties.
Embodiments of the disclosed transdermal composition may be comprised of a matrix of hydrated hydrophilic colloids of which coacervate compositions comprise one class of such colloids. Gels constitute another class. Other compositions that could be used to provide the substrate for the medicament in this invention include any gelled silicon media, petrolatum and the like. In this invention, a gel based upon any acceptable coacervate formulation is preferred.
Any of the described formulations which eventuate as -60- ~ 132~ r r ~
oral or parenteral products of this disclosure can constitute the basis for preparing the transdermal product. Medications that can be incorporated in the gel for transdermal administration include enzymes, biologicals, drugs and other useful medicaments. In short, any medically useful molecule capable of pene-trating the skin may be used in this invention. Use of the sonifier in conjunction with this composition acts in an unexpected manner to increase the rate of transdermal passage.
The method to produce a coacervate-based inhalant composition, as another embodiment of the present invention for administration of any suitable medication is as follows:
A method to prepare an inhalant medication is as follows:
Heat a mixture of about 7.5 gms of monogly-ceride and about 7.5 gms of diglyceride at a tempera-ture of from 70 to 75 C until a clear solution of the mixture is produced. Mix the desired amount of the pharmaceutical component into the solution. Next, process the product by means of a spray drying step to produce a powder form of the product. Next, make a suspension of the powder in lO0 mls of water contain-ing lO gms of polymerized albumin and lO gms of mono-meric lecithin. Stir the composition for about two minutes. Add an appropriate alcohol dropwise, n-butyl alcohol is preferred. During the addition of alcohol the product should be stirred gently until a coacervate forms and coats the particles with a coacer-vate film, to insure that coacervate encapsulation of the particles continues for from l/2 to 3 hours. After this step, adjust the pH to about 7.4 and if desired, and store for from 12 to 24 hours at about 4 C.
Following the storage step, the particles are separated from the liquid vehicle by filtration or other appropriate means. The particles are process--61- 132~ 2 ed using a colloid mill and/or a microfluidizer and sieving or other filtering procedures to produce par-ticles which are 1 micron or less in size. After this step, the quantity of particles necessary to S produce the required dose is mixed into any appropriate fluid, such as the liquid vehicle separated from the particles. The product comprises an inhalant medica-tion and is administered by nebulizer or other mist spraying apparatus.
The examples which follow are representative embodiments. They do not constitute the entire range of medications that can be used in this invention.

To 100 mls of a 10% w/v solution of poly-merized albumin add 10 gms of stroma-free hemoglobin from any appropriate source. Next, add about 2 milli-moles of glutathione and 8 gms of monomeric lecithin to the composition. Using a colloid mill and/or a microfluidizer, process the product for approximately 2 minutes. During this processing step add 10% of l ethyl-3 dimethyl aminopropyl carbodiimide (EDC). Fol-lowing this processing step store the composition for 12 hours at 4 C. The pH of the composition then is adjusted through the use of HCl or NaOH to approximate the pH of normal whole blood. This adjustment is made prior to the step of colloid mill and/or a micro-fluidizer processing and after the period of storage.
Isotonicity also is adjusted by adding plasma electro-lytes in such concentration as will approximate the isotonicity of whole human blood. This step is taken following the period of storage. Adjustment of vis-cosity to approximate that of whole human blood is made after the period of storage. At this point, the product may be used as a red blood cell substitute, provided that it is filtered to eliminate all extrane-ous matter and all particles larger than l micron in size. It is preferred that the product be processed .

-62- ~ 3~5~
further using a heating step designed to harden the coacervate-based film that envelopes the particle(s) con~aining the hemoglobin component. In the heating step, the composition is heated for 2 minutes at 70 C. Following this step the composition is filtered to eliminate all extraneous matter and all particles larger than l micron in size. Particles of l micron or less then can be put into an appropriate physiologi-cal fluid and transfused or stored at 4 C and recon-stituted as a red blood cell substitute (resusci-tation fluid) using an appropriate physiological fluid.

The procedure of Example l is followed except that polymerized lecithin is used in place of monomeric lecithin.

The procedure of Examine 2 is followed except that monomeric albumin is used in place of polymerized albumin.

The procedure of Example l is followed but, in addition, the encapsulated microparticles are sub-jected to a lyophilizing process to produce a powder form of the composition that can be mixed into an appropriate physiologic fluid as needed to produce a red blood cell substitute.

The procedure of Example l is followed except that 10% w/v of modified hemoglobin is used in place of stroma-free hemoglobin and about O.l~ urea is added.

The procedure of Example l is followed except that the heating step consists of heating the composi-tion at 50 C for l minute.

EXA~PLE , 13 2 ~
The procedure of Example 1 is followed except that stroma-free hemoglobin encapsulated in liposomes comprises the hemoglobin component.

Heat a mixture of about 7.5 gms of monogly-cerize and about 7.5 gms of diglyceride at a tempera-ture of from 70 to 75 C until a clear solution of the mixture is produced. Mix 15 gms of erythromycin into the glyceride solution thoroughly. The objective of the next step is to convert the composition to a powder form. This may be accomplished by any conven-tional form such as spray drying. In this instance the warm product comprised of the glyceride components and the erythromycin is gradually cooled to give a powder. The p~rticle size of~the product following the spray drying will range from about 2 microns to 500 microns. The finished product may consist of a single size or combination of sizes.
The next step is designed to coat the par-ticles with a coacervate film. The procedure is as follows. Make a suspension of the powder referred to above in 100 mls of water containing 10 gms of poly-merized albumin and 10 gms of monomeric lecithin.
Stir the composition for about two minutes. Add an appropriate alcohol dropwise, n-butyl alcohol is pre-ferred, until a coacervate forms and coats the parti-; cles with a coacervate film, stirring during the addi-tion of alcohol and afterward to insure that coacervate encapsulation of the particles continues for from 1/2 to 3 hours. The product is then stored for from 12 to 24 hours at about 4 C.
Following the storage step, the particles are separated from the liquid vehicle by fiItration or otber appropriate means and dried using any conven-~- tional method. This yields a finished oral product ~; of a coacervate coated pharmaceutically-active compon-:
',',' ~ :

~ ' , -64- 13~
ent, coated with the coacervate-based film. The pro-duct can be used to prepare capsules or reconstituted with an appropriate liquid(s), e.g., syrup, to produce a product with the desired clinical dose.

The procedure of Example 8 is followed, but in addition, the encapsulated microparticles are sub-jected to a lyophilizing process before prepared as capsules, tablets, or liquid preparations.

The process of Example 9 is followed except the product is divided into four portions. Portion 1 is heated at S0 C for 2 minutes; portion 2 is heated at 60 C for 2 minutes; portion 3 is heated at 65 C
for 2 minutes; portion 4 is heated at 70 C for 1-l/2 minutes. After the heating step, the products are combined thereby forming a sustained release composi-tion.

The process of Example 9 is followed except that the finished product of Example 9 is processed further by adding an additional coacervate (film) coat to the product as per the process of Example 9.
The resulting composition comprises a sustained release composition with two release rates.

The process of Example ll is followed except that 20% of the finished product is processed to re-ceive an additional coacervate (film) coat, two addi-tional coats (films) are applied to 30% of the product, and 50% of the product comprises the original finished product of Example ll. The products are mixed together thereby comprising a composition with sustained release characteristics, i.e., three release rates.

The procedure of Example 8 is followed except that regular insulin is used in place of erythromycin ~32~2 and in a quantity that will yield a finished oral composition containing 40 units of insulin per dose.

The procedure of Example 13 is followed except that regular insulin incorporated in liposomes is used in as the active component.

The procedure of Example 8 is followed, except that urokinase in an amount that will give unit dose of 50,000 IU is used in place of erythromycin and the encapsulated microparticles are subjected to a lyophilizing process to produce a powder which can be placed in capsules for oral use or used to recon-stitute a liquid dosage form by using an appropriate lS liquid.

The procedure of Example 8 is followed except that 15 gms of erythromycin encapsulated in liposomes is used..

The procedure of Example 8 is followed except that lidocaine is used in place of erythromycin and in a quantity that will yield a finished composition containing 1% lidocaine/5 ml per unit dose.

The procedure of Example 8 is followed except that 500 mgs of flourourocil encapsulated in liposomes is used as the active component.

The procedure of Example 11 is followed except that following the application of the additional coacervate coating to the product the composition then is heated at 70 C for 60 seconds.

The procedure of Example 8 is followed except that erythromycin is replaced with urokinase in an -66- ~ 132~ ~2 amount that will yield 50,000 IU of urokinase per unit dose.

The procedure of Example 20 is followed except that the urokinase component is encapsulated in liposomes.

This process consists of the following steps:
prepare polymerized albumin by adding 1 ethyl-3-di-methyl-aminopropyl-carbodiimide to a 10~ solution of monomeric albumin in an amount sufficient to produce a concentration of 5.0~ w/v EDC in the product. Pro-cess in a colloid mill and/or a microfluidizer for about 2 minutes. Next, store the product at about 4 C for about 10 hours. Mix into the product a solution of stroma-free hemoglobin to a concentration of about 10~ by weight of the composition and about 2 millimoles of NADPH into the product and process in a colloid mill and/or a microfluidizer for about 5 minutes;
following this step, mix into the solution polymerized lecithin in an amount sufficient to provide the solu-tion with a concentration of polymerized lecithin of - about 8~ by weight into the product, and process again in a colloid mill and/or a microfluidizer for about 3 to 5 minutes. Next, adjust the pH of the product to that of whole blood using HCl or NaOH as necessary.
Following this step, adjust the isotonicity using plasma electrolytes in such concentration as will give the product the isotonicity of whole human blood.
Adjust the viscosity as the next step so that the viscosity approximates that of whole blood. At this stage o manufacture the product may be used as a red blood cell substitute (resuscitation fluid) provided that it is first filtered to remove all extraneous matter and all particles that exceed 1 micron in size in any dimension. It is preferred, however, that the filtered product be processed further using either a ,.. . . . .

, ' ~ ' ' ' -67- 1 3 2 ~
chemical process based on a non-toxic crosslinking agent, such as gluteraldehyde, or a physical processing step, such as heat. The heating step is preferred and consists of heating the preparation for about 2 S minutes at a temperature that may range from about 50 C to about 70 C producing a film that can range from gel-like to rigid in character. Following this step, the resulting composition is filtered to remove all extraneous matter and any microencapsulated parti-cles that exceed 1 micron in size in any dimension.
The finished product of this invention can consist of particles of 1 micron or less in size with a minimal degree of surface film hardness or, alternatively, it can consist of particles of mixed surface film hard-lS nesses. The desired quantity of the particles can be added to any appropriate physiological fluid. As such, it will then comprise a product suitable for intravenous administration as a red blood cell substi-tute (resuscitation fluid). If desired, the microen-capsulated particles may be used in much the same manner as packed red blood cells. If desired, the product may be lyophilized or otherwise dried and reconstituted as a resuscitation fluid with any appro-priate physiologicaI fluid.
; 25 EXAMPLE 23 The procedure of Example 22 is followed except that polymerized lecithin is used in place of monomeric lecithin.

The procedure of Example 22 is followed except that stroma-free hemoglobin incorporated in liposomes is used in place of stroma-free hemoglobin.

The procedure of Example 22 is followed but in addition, the encapsulated microparticles are sub-jected to a lyophilizing process to produce a powder ~ form of the composition that can be mixed into an ... . . .

'' -' -68- 1~2~2 appropriate physiological fluid to produce a red blood cell substitute.

The procedure of Example 22 is followed S except that 10% w/v of modified hemoglobin is used in place of stroma-free hemoglobin.

The procedure of Example 22 is followed except that the heating step consists of heating the composition at 50 C for 2 minutes.

The procedure of Example 8 is followed, except that erythromycin is replaced with heparin in an amount that will give 1000 USP units/ml in the finished product; the composition is subjected to a lyphilizing process to produce a powder form of the composition which can be prepared as tablets or cap-sules or reconstituted using any appropriate pharma-ceutical fluid thereby comprising a useful oral medica-tion.

The procedure of Example 1 is followed exceptthat (1) 5 gms of erythromycin replaces the hemoglobin and (2) the steps involving glutathione and the addi-tion of 1-ethyl-3 dimethyl aminopropyl-carbodiimide are omitted. The step to adjust the pH of the composi-tion to approximately 7.4 is made after the storage period. After the heating and filtering steps, the microparticles are dispersed in any appropriate physio-logical fluid. The product then is ready for parenter-al administration or stored, preferably under refri-geratio~, until needed.

The procedure of Example 29 is followed except that urokinase is used in place of erythromycin in a quantity that will yield a finished composition containing 50,000 IU of urokinase per unit dose.

EXAMPLE 31 1~2i~4~, The procedure of Example 29 is followed except that 500 mgs of flourouracil is substituted for erythromycin and the sizes of the microparticles of the finished product range from less than 1 micron to 4 microns, The procedure of Example 1 is followed except that 10% w/v of erythropoietin is used in place of hemoglobin, and the steps involving the use of gluta-thione and 1 ethyl-3-dimethyl aminopropyl carbodiimide are omitted, The finished product comprises a useful intravenous composition of erythropoietin. The product can be lyophilized to produce a powder form of the composition and stored under refrigeration or recon-stituted with an appropriate physiological fluid for intravenous administration.

The procedure of Example 22 is followed except that 10% w/v of modified hemoglobin is used in place of stroma-free hemoglobin.

The procedure of Example 31 is followed except that the flourouracil is encapsulated in micro-particles of 2 to 4 microns in size. This product iscombined with the erythromycin product of Example 29;
the mixture comprising an intravenous composition composed of two active components with differing par-ticle sizes, eryrhtomycin 1 micron or less; flouroura-cil 2-4 microns.

The procedure of Example 22 is followed, except that the stroma-free hemoglobin encapsulated in liposomes is used as the starting hemoglobin compon-ent, EXAMPLE 36 13 ~ 2 The procedure of Example 22 is followed but, in addition, the encapsulated microparticles are subjected to a lyophilizing process to produce a powder S form of the composition that can be stored at 4 C or reconstituted with an appropriate physiologic fluid to produce a red blood cell substitute (intravenous).

The procedure of Example 31 is followed except that the erythromycin and flourourocil incor-porated in liposomes are used as the active components.

The procedure of Example 22 is followed except that 275 mgs of erythromycin is used in place of the hemoglobin component and the steps involving the use of NADPH and 1 ethyl-3-dimethyl-aminopropyl carbodiimide are omitted. The step in which the pH
is adjusted to approximately 7.4. is made after the storage period. After the heating and filtering steps, the microparticles are dispersed in any appropriate physiological fluid. The product is then ready for intravenous administration or it may be stored, prefer-ably at 4 C.

The procedure of Example 38 is followed except that leuprolide in a quantity that will yield leuprolide mg/0.2 ml in the finished product is sub-stituted for erythromycin.

The procedure of Example 39 is followed, except that urokinase in that quantity as will give 50,000 IU activity per dose in the finished product is used in place of leuprolide and the product is lyophilized. The product can be reconstituted with an appropriate physiological fluid for intravenous use.

-71~ J ~ ~ r~J

The procedure of Example 40 is followed except that 60,000 IU of urokinase incorporated in liposomes, is used as the active component.

The procedure of Example 40 is followed except that 500 mgs of flourouracil replaces urokinase and is processed so that the particle size of the particles ranges from 2-4 microns and the product of Example 38 is mixed with the product of this Example.
This comprises an Example of a combination of two compositions, each with a different particle size.

Mix to a concentration of 10% w/v stroma-free hemoglobin into a solution of polymerized lecithin of about 20~ concentration. Process the product in a colloid mill and/or a microfluidizer for about 2-3 minutes. Mix ascorbic acid of at least 0.1 gm per 100 ml of solution and an amount equal to 10% w/v (100 units/cc. in the finished product) of polymerized albumin into the product and process the resulting product in a colloid mill and/or a microfluidizer for about 5-7 minutes. Next, store the product for about 10 hours at 4 C. Adjust the pH of the preparation after the period of storage to about 7.4 using HCl or NaOH as necessary. Following this step, add electro-lytes present in human plasma in such amount as will give the product the isotonicity of whole human blood.
Next, adjust the viscosity of the product so that it approximates the viscosity of whole human blood. On completion of this step, the product comprises a micro-emulsion that consists of microencapsulated particles containing the hemoglobin component. At this stage of manufacture the product may be used as a red blood 3S cell substitute (resuscitation fluid) provided that it is first filtered to remove all extraneous matter and all particles that exceed 1 micron in size in any -72- 1~2~ ~c~
dimension. It is preferred, however, that the filtered product be heated for about 2 minutes at about 70 C.
The product then is filtered to remove all extraneous matter and all microencapsulated particles which exceed l micron in any single dimension. ~fter this step, the product may be used as an intravenous blood sub-stitute or stored, preferably at 4 C, until needed.

The procedure of Example 43 is followed except that stroma-free hemoglobin incorporated in liposomes is used in place of stroma-free hemoglobin.

The procedure of Example 43 is followed but in addition, the encapsulated microparticles are sub-jected to a lyophilizing process to produce a powder form of the composition that can be mixed into an appropriate physiological fluid to produce a red blood cell substitute.

The procedure of Example 43 is followed except that 10% w/v of modified hemoglobin is used in place of stroma-free hemoglobin.

The procedure of Example 43 is followed except that the heating step consists of heating the composition at 50 C for about 2 minutes.

The procedure of Example 43 is followed except that (l) 275 mgs of erythromycin replaces the hemoglobin component. The step in which the pH is adjusted to approximately 7.4. is made after the stor-age period. After the heating and filtering steps, the resulting microparticles are dispersed in any appropriate physiological fluid. The product then is ready for intravenous administration or storage at 4 C.

EXAMPLE 49 13215~.~
The procedure of Example 43 is followed, but in addition, the composition is lyophilized to produce a powder form of the product which can be reconstituted with any appropriate physiological fluid.

The procedure of Example 48 is followed, except that 500 mgs of flourouracil is used in place of erythromycin and the sizes of the micropar~icles are in the range of 2 to 4 microns.
EXAMPLE 5l The procedure of Example 50 is followed - except that the flourouracil is encapsulated in lipo-somes before being encapsulated within the coacervate composition.

~ The procedure of Example 48 is followed - except that leuprolide in a quantity that will yield leuprolide mg/0.2 ml in the finished product is sub-stituted for erythromycin.

The procedure of Example 8 is followed except that 200 mgs. of ibuprofen is used in place of erythro-mycin.

The procedure of Example 43 is followed ~ , except that 10% w/v of erythropoietin is used in place of hemoglobin and the step involving the use of as-~; ~ corbic acid is omitted. The finished product comprises M~ - 30 a useful intravenous composition of erythropoietin.
, ; ~ The product of Example 48 is mixed with the product of Example 50 to produce a combination of two compositions with differing particle sizes.

The procedure of Example 48 is followed ~; except that leuprolide is used in place of erythromy-.

-74~ ~ r '1 cin, and in an amount that will give 4 mgs/0.2 ml of leuprolide in the finished product.

The procedure of Example 48 is followed S except that erythromycin is replaced with urokinase in an amount that will give 50,000 IU per dose in the finished product.

The procedure of Example 56 is followed, except that the leuprolide component is encapsulated in liposomes.

The procedure of Example 8 is followed except that after the addition of n-butyl alcohol and the stirring step, about 10% w/v of pectin is mixed into the product now comprised of the microparticles separ-ated from the vehicle. After the step in which pectin is added, the pH of the composition is also adjusted using either HCl or NaOH as required to about 7.4.
The product comprises a composition that can be ad-ministered transmucosally and/or transdermally.

The process of Example 53 is followed except that 5% nitroglycerin is used to replace erythromycin and 5% w/v of albumin is used in place of pectin.
The finished product comprises a transmucosal medica-tion.
EXAMPLE 6l The process of Example 59 is followed except that 5 mg/ml of lidocaine replaces the nitroglycerin.

The procedure of Example 59 is followed except that a heating step of about 50 C for 40 seconds replaces the step using n-butyl alcohol. Fol-lowing heating, the product is processed to separatethe microparticles from the vehicle. About 10% w/v pectin is mixed into the resulting microparticle com-- ~75~ - ~32~2 position. During the step in which the pectin is added, the pH of the product is adjusted to about 7.4 using either HCl or NaOH as required.

The procedure of Example 59 is followed except that 5% nitroglycerin is used in place of erythromycin; storage of the composition at room tem-perature for about 24 hours replaces the heating step.

The procedure of Example S9 is followed except that 5% w/v albumin replaces pectin and 10%
nitroglycerin is used.

The process of Example 59 is followed except that 5% nitroglycerin is used to replace erythromycin and 5% w/v of albumin is used in place of pectin.
The finished product comprises a transmucosal medica-tion.

The process of Example 65 is followed except that 5 mg/ml of lidocaine replaces the nitroglycerin.

The process of Example 66 is used except that 100 units of regular insulin is used instead of lidocaine.

The process of Example 59 is followed except that 0.1% ascorbic acid is added at the same time pectin is added.

The process of Example 62 is used except that 100 units of insulin is used instead of erythromy-cin.

The process of Example 62 is used except that 0.2% ascorbic acid is added when pectin is added.

EXAMPLE 71 ~ 1~ 2 ~
The procedure of Example 62 is followed except that 40 units of insulin is used in place of erythromycin; storage of the composition at room tem-perature for about 24 hours replaces the heating step.

Mix about 10 gms of lecithin into about 10 cc of carbon tetrachloride. Add S gms of erythromycin to the solution. Spray dry the product until all traces of carbon tetrachloride are removed. The re-sulting product will be comprised of powder-like par-ticles comprised of erythromycin and covered by a film of lecithin. Next, make a suspension of the powder in 100 mls of water containing 10 gms of poly-merized albumin and 10 gms of monomeric lecithin.
Stir the composition for about two minutes. Add an appropriate alcohol dropwise, n-butyl alcohol is pre-ferred. During the addition of alcohol the product should be stirred gently until a coacervate forms and ~0 coats the particles with a coacervate film. Stirring continues for from 1/2 to 3 hours to insure coacervate encapsulation of the particles. After this step, adjust the pH to about 7.4 and if desired, store for from 12 to 24 hours at about 4 C.
Following the storage step, the particles are separated from the liquid vehicle by filtration or other appropriate means and dried using any conven-tional method. This yields a finished oral product comprised of coaceravate coated erythromycin. The product can be used to prepare tablets, capsules or reconstituted with an appropriate liquid(s), e.g., syrup, to produce a product with the desired clinical dose.

Mix about 10 gms of lecithin into about 10 cc of carbon tetrachloride. Add 3 gms of erythromycin into the solution. Distill the product until all ,~
. .,~. . :

traces of the carbon tetrachloride are removed and the product, comprised of lecithin and erythromycin, is in the form of a viscous residue. Mix about 50 mls of a 10% solution of albumin into the product.
S Add 100 mls of distilled water and centrifuge the composition for about 10 minutes at about 2500 rpm.
The particles now separated from their vehicle are collected. They comprise an oral erythromycin coated by a coacervate film.

The method of Example 73 is followed except that the steps that begin with the addition of the albumin component are repeated.

The process of Example 72 is followed except that the product of Example 72 is converted to a sus-tained release preparation using the following method.
Make a suspension of the powder referred to above in 100 mls of water containing 10 gms of polymerized albumin and 10 gms of monomeric lecithin. Stir the composition for about two minutes. Add n-butyl alcohol dropwise until a coacervate forms and coats the par-ticles with a coacervate film, stirring continues for from 1/2 to 3 hours during the addition of alcohol and afterward to insure coacervate encapsulation of the particles. The product is then stored for from 12 to 24 hours at about 4 C.
Following the storage step, the particles are separated from the liquid vehicle by filtration and dried. The resulting composition comprises a sustained release medication useful for oral adminis-tration.

The process of Example 74 is followed except that the product of Example 74 is converted to a sus-tained release preparation using the following method.
Make a suspension of the powder referred to above in -78- 13 ~ ~k~J
100 mls of water containing 10 gms of polymerized albumin and 10 gms of monomeric lecithin. Stir the composition for about two minutes. Add n-butyl alcohol dropwise until a coacervate forms and coats the par-S ticles with a coacervate film, stirring continues forfrom 1/2 to 3 hours during the addition of alcohol and afterward to insure coacervate encapsulation of the particles. The product is then stored for from 12 to 24 hours at about 4 C.
Following the storage step, the particles are separated from its liquid vehicle by filtration and dried. The resulting composition comprises a sustained release medication useful for oral adminis-tration.

Mix about 6 gms of lecithin in about 200 mls of water; add about 24 mls of an appropriate alco-hol such as n-butyl alcohol dropwise to the mixture.
Next mix a solution comprised of about 3 gms of NaCl and about 60 mls of water into the lecithin-alcohol composition and allow to stand until a two phase coa-cervate is produced. Separate the two phases and add 20% acetylcysteine to the coacervate phase. Mix thoroughly. The pH is adjusted to about 8.0 after which the composition containing the medication may be administered by nebulizer which sprays a mist of the particles having a particle size of 1 micron or less.

The process of Example 77 is followed except that 5 gms of lecithin is added to the coacervate phase in place of acetylcysteine and the pH is adjusted to about 7.4 using HCl or HaOH as required.

The process of 77 is followed except that the lecithin-coacervate phase, per se, is adjusted to a pH of about 7.4 and used as an inhalant medication.

- 1 3 2 ~ c ~

Heat a mixture of about 7.5 gms of monogly-ceride and about 7.5 gms of diglyceride at a tempera-ture of from 70 to 75 C until a clear solution of S the mixture is produced. Mix 15 gms of erythromycin into the glyceride solution thoroughly. Next, process the product by means of a spray drying step to produce a powder form of the product. Next, Make a suspension of the powder in 100 mls of water containing 10 gms of polymerized albumin and 10 gms of monomeric leci-thin. Stir the composition for about two minutes.
Add n-butyl alcohol dropwise until a coacervate forms and coats the particles with a coacervate film, stir-ring for from 1/2 to 3 hours during the addition of alcohol and afterward to insure coacervate encapsula-tion of the particles. The product is then stored for from 12 to 24 hours at about 4 C.
Following the storage step, the particles are separated from the liquid vehicle by filtration or other appropriate means. The particles are process-ed using a colloid mill and/or a microfluidizer and sieving procedures to produce particles which are 1 micron or less in size. After this step, the quantity of particles necessary to produce the required dose is mixed into any appropriate fluid including the liquid vehicle referred to above. The product com-prises an inhalant medication and is administered by nebulizer or other mist spraying apparatus.

The method of Example 77 is followed except that 15 gms of erythromycin is used in place of acetyl-cysteine and the pH adjustment is made to about 7.4.

The procedure of Example 1 is followed except that (1) 275 mgs of erythromycin is dispersed in oleic acid of about 10% w/v as the first step of the process and the step using the reducing agent is omitted.

-80- ~ 13~k2 The step to adjust the pH of the composition to ap-proximately 7.4. is made after the storage period.
After the heating and filtering steps, the micropar-ticles are dispersed in any appropriate physiological S fluid. The product is then ready for oral administra-tion or stored, preferably under refrigeration, until needed. The composition may be administered orally, if desired.

The procedure of Example 82 is followed except that the object of the heating step in this method is to produce microparticles which are gel-like in character. The composition is heated at about 60 C for about 45 seconds. The resulting composition lS then is centrifuged to separate the particles from the vehicle of the product; following this step, about 10% w/v of pectin and about 0.1% of ascorbic acid are mixed into the product now comprised of the micropar-ticles separated from the vehicle. During the steps in which pectin and ascorbic acid are added, the pH
of the composition is also adjusted using either HCl or NaOH as required to about 7.4. The product com-prises a nasally or rectally administered medically useful composition. The addition of ascorbic acid can be omitted.

The procedure of Example 83 is followed except that in place of the heating step, the product is stored at room temperature for about 24 hours and 5% nitroglycerin is used in place of erythromycin.

The procedure of Example 84 is followed.
The f inished product however is applied to the skin.
The drug is released from the composition and enters the circulation through the skin.

: ,:
, , .., ,,,,:.

EXAMPLE 86 1 ~2~ ~Lf~
The procedure of Example 84 is followed except that 4000 mcg of vitamin B-12 is used in place of erythromycin.

The procedure of Example 84 is followed except that 4 mgs/0.2 ml of leuprolide is used in place of erythromycin.

The procedure of Example 87 is followed except that the composition is administered rectally either in the form of an ointment or a suppository.

The procedure of Example 86is followed except that the composition is applied to the skin, thereby comprising a transdermal preparation.

The procedure of Example 82 is followed with the following exceptions: The heating step con-sists of heating the composition for about 45 seconds at about 50 C and the adjustment of the pH takes place at a different point in the manufacturing pro-cess. Following the heating step, the microparticles are separated from the vehicle and about 10~ pectin and about 0.1% ascorbic acid are mixed into the compo-sition comprised of the microparticles. During this step, the pH of the product is adjusted to about 7.4 using HCl or NaOH as required. The finished product comprises a nasally or rectally administered medically useful composition.

The procedure of Example 90 is followed except that 5 mg/ml of lidocaine is used in place of erythromycin.

132~

The procedure of Example 91 is followed except that the composition is applied to the skin, thereby comprising a transdermal preparation.

The process of Example 83 is followed except that 10 mgs/ml of ephredrine is used in place of erythromycin.

The procedure of Example 93 is followed - except that the preparation is applied to the skin thereby comprising a transdermal preparation.
In accordance with another important embodi-ment of the method used to prepare both oral and paren-lS teral compositions, the drug-containing coacervate - compositions are prepared by (a) dissolving a phospho-lipid in water and adding thereto an alcohol in an amount which will cause the phospholipid-water-alcohol preparation to separate into~three immiscible layers wherein the lowest layer is colloid-poor, the middle layer is colloid-rich, and the upper layer i9 alcohol;
~b) separating the middle phase, the nonpolar, colloid-rich phase, from the other two phases; and (c) adding ~ , a water-insoluble drug to a colloid-rich phase in such quantity as will produce a solution containing ;~ ~ the drug component in the desired dosage for oral, tissue lining absorptive or parenteral administration.
' ~ ~ The colloid-poor lower phase may be used to solubilize water-soluble compounds. Either the colloid-rich or colloid-poor phases or a combination of both phases may be used to encase the physiologically active com-pounds. Additionally, the drug delivery compositions of the present invention can be prepared in the form ~-~ of microencapsulated sustained release formulations , , , ; 35 (emulsions) of orally, tissue lining absorptive, or parenterally administrable drugs. The microencap-sulated particles range in size from less than abut , :

-83- - ~ 3 ~
l~0 nanometers to about 3 microns or larger. In the practice of the time-release embodiment of the present invention, the final composition or product may be composed of particles of the same or different sizes, with differing time-release characteristics.
In accordance with the preferred method of this embodiment of the present invention, an alcohol, such as isopropyl alcohol, is added dropwise to a 4%
w/v aqueous solution of one or more surface active agents, such as albumin, until a two-phase liquid aqueous system is produced. The two phases are separ-ated. The upper phase is referred to as the colloid-rich phase; the lower phase known as the colloid-poor phase is discarded or stored for later use to prepare additional quantities of the coacervate composition.
A 4% w/v quantity of dry lecithin powder is dissolved in the colloid-rich pbase creating an albumin-lecithin based colloid-rich phase. The oral or parenteral drug to be used is dissolved in the colloid-rich phase as described with reference to the three-phase embodi-ment of manufacture. The finished composition of this embodiment of the present invention can be pre-pared either as an emulsion or as a suspension.
A critical distinction between the coacer-vate-based blood substitute compositions identified in prior patents and the compositions of this embodi-ment of the present invention is in the addition of an appropriate alcohol to a composition to form a two-phase coacervate composition with alcohol on top as an upper third layer or phase. The middle coacer-vate phase then is separated out and a phospholipid, such as lecithin, is added thereto. A second coacer-vate composition results therefrom and is used to formulate the coacervate compositions of this embodi-ment for new and unexpected stability. As an option,the middle coacervate phase can be used without the addition of the phospholipid.

-84- 132~2 In accordance with the principles of the preseht invention, any appropriate non-toxic coacervate composition can be used in the manufacture of the drug delivery compositions of the present invention.
S The coacervate-enveloped compositions of the present invention incorporate non-toxic endogenous or exogenous surface-active agents, derivatives thereof and/or combinations of surface-active agents or derivatives.
To achieve the full advantage of the alcohol embodiment of the present invention, the coacervate compositions include a phospholipid, such as lecithin;
a protein with surface-active properties, such as albumin; an alcohol such as n-butyl alcohol and water.
Any drug, particularly drugs administered lS parenterally or absorbed through the tissue lining, drugs which are prepared and administered at an exces-sive pH, parenteral drugs that require pH adjustment immediately prior to injection and any salt of a parent drug compound which has been neutralized by means of the proper acid-base reaction to yield the parent compound may be used as the drug component in the orally, tissue lining absorbed, or parenterally ad-ministrable coacervate based film-enveloped compo-sitions of the present invention.
It should be noted that while the composi-tions of the present invention stabilize and solubilize oral, tissue lining absorbed and parenteral drugs as de8cribed, some dissolution of the drug also occurs in accordance with the principles of the present inven-tion, Either the colloid-rich phase of the two-phase liquid aqueous coacervate composition, the col-loid-poor phase, or a combination of the colloid-rich and the colloid-poor phases of the compositions may be used to produce the outer coacervate based film enveloping the physiologically active compounds as orally, tissue lining absorptive, or parenterally : . :
,"
.~, , -85- 1~2~
administrable compositions of the present invention.
To achieve the full advantage of the present invention, the physiologically active compound(s) are incorporated into the colloid-rich phase of the composition. The colloid-poor phase can be used to incorporate and deliver formulations of water-soluble, polar and semi-polar drugs. Administration of the formulations of this invention may be oral; absorbed through the tissue lining of the mouth, nasal passages, or rectum; intra-venous; intramuscular or subcutaneous, as desired.
Drug compositions commonly understood to bewater-insoluble, as defined in the U.S. Pharmocopia, now can be solubilized in an aqueous media by use of the present drug delivery compositions. Further, the compositions of the present invention provide a basis for improving the manufacture and efficacy of literally hundreds of orally, tissue absorptive, and parenter-ally administered drugs.
A preferred two-phase liquid aqueous coacer-vate composition in accordance with the alcohol embodi-ment of the present invention is prepared using the following steps. To lO0 mls of sterile, pyrogen-free water are added 1-6~ w/v of lecithin, derived from egg or other acceptable sources. The mixture is mixed or shaken vigorously until the lecithin is thoroughly dissolved. 6 to 12 mls or more of any acceptable alcohol, particularly a lower alcohol having l to about 6 carbon atoms, such as ethyl alcohol, n-butyl alcohol, and the like then is added to the lecithin solution, and the solution then is shaken vigorously for from lO to 30 sèconds and set aside, undisturbed, for from less than l to more than 4 hours. Within this period of time, the solution will separate into three phases or layers. If at the end of two hours the phases have not separated out, additional alcohol may be added dropwise until the separation of phases occurs. If desired, the period of undisturbed storage ,, -86- - ~ 3~ 2 may extend to 24 hours or longer. Longer periods of storage typically result in greater yields of the coacervate phase. At the close of the storage period, it will be observed that three layers have formed.
S The uppermost layer comprised of n-butyl alcohol is separated from the other phases such as by decanting or through a separating funnel, and set aside since it is now extraneous to the coacervate system. The middle layer comprises approximately 50 mls. of a collo-d-rich coacervate phase and the bottom layer comprises approximately 50 mls of a colloid-poor (equi-librium water) phase. The proportions of the bottom and middle phases may vary from 0.5% to 99.5%, based on the volume of both layers.
lS After separation of the phases is completed, from 1 to 2 grams of a su~face active protein such as human serum albumin, is dissolved in the colloid-rich coacervate phase of the solution to form a second coacervate system or composition. The preparation is then stored, preferably under refrigeration at 4-10 C, until visual inspection indicates that the prepara-tion has separated into two phases. The upper layer comprises the colloid-rich phase of the second coacer-~; vate composition; the bottom layer comprises the col-loid-poor phase of the second coacervate composition.
The two phases can be separated, such as by decanting, and a desired dosage o a drug or other physiologically active compound is dissolved in either the colloid-rich~phase and/or the colloid-poor phase to provide an injectable, orally, or tissue absorptive adminis-trable composition. If desired, the quantity of drug combined into the coacervate composition may be more or less than a standard dose to provide a modified clinical dose. Additionally, if desired, urea in an amount that may range of 1% to 40% w/v may be added to the coacervate phase, prior to the addition of the ., :' .~, -87- 13~ 2 drug component to make the coacervate phass less non-polar.
In accordance with another important embodi-ment of the present invention, a monoglyceride, digly-ceride and/or a triglyceride is included in the coacer-vate composition as a li~uid vehicle for dispersing or solubili~ing one or more physiologically active compounds therein. The vehicle containing the physio-logically active compound dissolved or dispersed there-in then is enveloped in one or more exterior layers of a coacervate based film in order to provide new and unexpected stability to the orally, tissue absorp-tive or parenterally administrable compositions. As used herein, the term "triglycerides" refers to short chain, medium chain, long chain, and hydrogenated triglycerides. In this invention monoglycerides and diglycerides may be used as an option. Combinations of mono, di, and triglycerides also may be used.
Medium chain triglycerides are preferred. In an op-tional process, physiologically acceptable halogenated compounds, particularly halogenated hydrocarbons may be substituted for the glyceride component of the compositions of the present invention. The preferred halogenated chemicals are the perfluorohydrocarbons, such as perfluorodecalin. Suitable other perfluoro-chemicals include perfluorotributylamine, perfluoro-N,N dimethylcyclohexylmethylamine, perfluorotripropyl-amine and perfluorotrimethylbicyclo(3.3.1)nonane.
Other suitable halogenated hydrocarbons include halo-thane (2-bromo-2-chloro-1,1,1-trifluoroethane) and methoxyflurane(2,2-dichloro-1,1-difluoroethylmethylester).
All components~may be prepared, combined andjor mixed under sterile conditions. The water used in manufacturing the coacervate system should be sterile and pyrogen-free for intravenous preparation.
In accordance with this embodiment, the .~ ~
pharmaceutical component or combinations thereof are ~ ::

,, :

, . ., ' .

-88- 1~ 2 dissolved in a glyceride, preferably a medium chain triglyceride, preferably 30% w/v, containing a pharma-ceutical component solubilizing agent, such as a hy-deogenated oil, oleic acid, or linoleic acid preferably S 10% w/v, based on the weight of the triglyceride to substantially increase stability. The triglyceride may be 1% to 80~ w/v of the composition and may be a monoglyceride or a diglyceride or mixtures of one or more mono, di, or triglycerides. The solubilizing agent may be added to the glyceride in an amount of about 0% to about 50% by weight of the glyceride, for example, 10% hydrogenated vegetable oil or oleic acid, whenever needed for complete solubilization of physio-logically active components. The glyceride component may be composed of short chain (up to C9), medium chain ~C9 to C18), long chain (above C18) and/or hydro-genated triglycerides or combinations thereof depending upon the composition to be prepared. Medium chain (C9 to C18) triglycerides are preferred. The quantity of the pharmaceutical component(s) mixed into the triglyceride may range from 0.1% to 15% in excess of conventional clinical doses. The individual dose of ~ the pharmaceutical component(s) of the finished compo-; sition is adjusted as necessary to meet clinical re-quirements.
The preferred method of the triglyceride embodiment of the present invention also provides for preparation of sustained release forms of the micro-emulsions described above. This process involves the following steps: (1) Mix the desired quantity of the pharmaceutic component(s) into a solution contain-ing that quantity of a medium chain triglyceride con-taining 10% hydrogenated oil as will comprise 30% w/v in the finished product; the w/v concentration of the triglyceride component may vary from 1% to ~0% w/v;
30% w/v is preferred; the quantity of the pharmaceutic component(s) used can range from 0.01% to 15% in excess "~ , ~
., .~ , ~,. . .

.

-89- ~ , c of established clinical doses; in the finished product, the individual dose is adjusted to clinical require-ments. (2) Prepare a second solution comprising 5%
w/v of albumin; mix the same pharmaceutic component(s) used in step 1 into the albumin solution in an amount that may range from 25% less than the established clinical dose to 15% in excess of the established clinical dose; 3% w/v of lecithin then is mixed into the product of step l; this mixture is repeatedly passed through an appropriate colloid mill to product a microemulsion, the particles or droplets of which are one micron or less in size; it is preferred that heat, in a range from 30 C to 70 C~ be applied dur-ing the mi~roemulsifying step; in an alternative pro-cedure, the heating step may be deferred until the microemulsion has been formed, as describea.
Specific examples of the alcohol and gly-ceride embodiments of the present invention are provid-ed in the following examples 127-160.

To 100 mls of sterile, pyrogen-free water is added 4~ w/v of egg lecithin. The mixture is stirred vigorously until the lecithin is thoroughly dissolved. 10 to 12 mls of n-butyl alcohol then are added to the lecithin solution, which is then shaken vigorously for from 1 to 2 hours. At the close of the storage period, it is observed that three layers or phases have formed. The middle layer comprising the colloid-rich phase is separated from the other phases by means of a separatory funnel. 1 to 3 grams of human serum albumin then is dissolved in this col-loid-rich phase. The solution tfien is stored at from 4 to 10 C until visual inspection indicates that this solution has separated into two phases and that no increase in the volume of said phases is occurring.
The two phases then are separated by means of a separa-tory funnel. That quantity of diazepam is added to g o 1 3 f the colloid-rich phase as will result in a final con-centration of 5 mg of diazepam per milliliter of coa-cervate solution. After this step, the colloid-poor (lower) phase is mixed into the colloid-rich phase.
S The resulting mixture then is emulsified to produce a microemulsion. The pH of the microemulsion then is adjusted, if necessary, to 7.3-7.4 by the dropwise addition of dilute hydrochloric acid or sodium hy-droxide. The preparation then can be stored in suit-able containers for use orally or by injection.

The procedure of Example 95 is followedexcept that prior to storage or administration, the composition is heated to produce a sustained (time-lS release) preparation. The preparation described inExample 1 is heated at 70~ C for 60 seconds. The resulting microencapsulated droplets are separated from the emulsion, washed thoroughly with sterile water, then dried thoroughly and dispersed in any appropriate vehicle for parenteral or oral use, for example, to provide a composition containing 5 mg of diazepam per milliliter of solution. On completion of this step, the composition may be administered orally, by injection or stored in suitable containers until needed.

The procedure of Example 95 is followed except that 10 mls. of a commercial preparation of diazepam is used in place of diazepam (parent com-pound).

The procedure of Example 96 is followedexcept that 5 mgs of diazepam is used in place of the commercial parenteral preparation of diazepam.

-91- ~ r~ ~'1 ,i The procedure of Example 95 is followed except that 50 mgs of a commercial p~eparation of phenytoin is used instead of diazepam.

The procedure of Example 96 is used except that 50 mgs of a commercial parenteral preparation of phenytoin is used in place of diazepam.

The procedure of Example g5 is followed except that 50 mgs of phenytoin, as the parent com-pound, is used.

The procedure of Example 96 is followed lS except that 50 mgs of phenytoi~, as the parent com-pound, is used in place of diazepam.

The procedure of Example 95 is followed except that 7 mls of diazepam are used.

The procedure of Example 95 is followed except that 100 mgs of a commercial intramuscular parenteral preparation of tetracycline HCl is used in place of diazepam.

The procedure of Example 96 is followed except that 100 mgs of a commercial intramuscular preparation of tetracycline HCl is used in place of diazepam.

The procedure of Example 95 is followed except that 100 mgs of a crystalline tetracycline is used in place of diazepam.

The procedure of Example 106 is followed except that 250 mgs of a commercial intravenous pre-paration of tetracycline HCl (neutralized) reconsti--92~
tuted as per the manufacturer's directions is used instead of diazepam.

The procedure of Example 95 is followed except that preparation of the composition is completed when the diazepam is dissolved in the colloid-rich phase of the coacervate system. The preparation is then ready for oral or parenteral administration or storage.

The procedure of Example 95 is followed except that preparation of the composition is completed when the phenytoin is dissolved in the colloid-rich phase in place of diazepam. The preparation then may be orally or parenterally administered or stored as required.

The procedure of Example 95 is followed except that tetracycline is dissolved in the colloid-rich coacervate phase in place of diazepam. The pre-paration is then ready for oral or parenteral adminis-tration or storage.

The procedure of Example 95 is used to the point where the colloid-rich phase is separated from the colloid-poor phase. Instead of using the colloid-rich phase to dissolve the drug component, the colloid-poor phase is used to incorporate the drug component.
Thus, 5 mls of commercial trimethoprinsulfamethazole infusion is thoroughly mixed into 125 mls of the col-loid-poor phase. The preparation then is ready for infusion.

The procedure of Example 111 is followed 3S except that after the drug is mixed into the colloid-poor phase, 125 mls of the colloid-rich phase is added _93_ 1 3 ~ ~ cr ~
and the preparation emulsified. The composition then may be infused.

The procedure of Example 96 is followed S except that glucagon, in any quantity ranging from 0.5 mg to 1.0 mg, is substituted for the diazepam.
If desired, from 25 mgs to 150 mgs of lactose is added to the preparation following the addition of glucagon.

The procedure of Example 96 is followed except that 0.5 mg of glucagon is substituted for the diazepam.

The procedure of Example 95 is followed lS except that Methyldopate HCl is used instead of diaze-pam and 1~ w/v of urea is added prior to the incorpora-tion of the drug component.
EXAMP~E 116 Melt the solid form of 15% w/v of long chain triglycerides and 15% w/v medium chain triglycerides.
Add 250 mg of erythromycin to the melted product and add 5 ml of an aqueous solution containing 5% albumin and 3% lecithin to this mixture to provide about 250 mg. of erythromycin in the colloid-rich phase. Mix the resulting product and permit the composition to slowly cool to room temperature. If the product is to be used intravenously, adjust the pH and isotonicity as described previously. If the finished product is to be administered orally, adjustment of the pH and isotonicity is optional. Process the product through a colloid mill. This will produce a microsuspended composition having solid microparticles comprised of the pharmaceutic component(s) encapsulated by a tri-glyceride/coacervate film. While the intravenous product should consist of particles one micron or less in size, oral compositions may have a mixture of 94 - 13 ~i~Jl~2 particle sizes ranging from a nanometer to 10-15 mi-crons.

The procedure of Example 116 is followed except that 1000 units/ml per unit dose of heparin is used in place of erythromycin.

Example 95 is followed except 10 ml of Factor VIII is substituted for diazepam.

Example 9S is followed except 30 ml of Factor IX complex is substituted for diazepam.

Example 95 is followed except 250 mg of lS atrial peptide 3 is substituted for diazepam.

-~ 14% by weight of hemoglobin is encapsulated in a liposome product and then the liposome is placed in the coacervate phase of Example 9S. The remaining procedure is the same as Example 95.

The procedure of Example 95 is followed except that nutritional quantities of L clonine, L
argiuine, L aspartic acid, L glutamine, glysine, L
histidine, L proline, L servine, and L tryosine also are added.

The procedure of Example 95 is followed except that the diazepam component is first enveloped in a liposome. The resulting product then is mixed into the coacervate phase and processed in the manner described in Example 127.

The procedure of Example 123 is followed except that 5 mg of heme is used in place of diazepam.

.,., ~ ~ , .

.' , " , ~ 3 2 ~

The procedure of Example 123 is followed except that 2,500,000 I.U. of urokinxse is used in place of diazepam.

The procedure of Example 123 is followed except that, that amountof erythromycin as will give 250 mg of erythromycin in the finished product is used in place of diazepam.

The procedure of Example 123 is followed except that, that amountof insulin as will result in a finished product containing 40 units of insulin is used in place of diazepam.

The procedure of Example 123 is followed except that, that amount of stroma free hemoglobin as will result in a inished product containing 14 percent by weight of stroma free hemoglobin is used in place of diazepam.
In accordance with another important embodi-ment of the present invention, compositions capable of oral or intravenous administration, can be prepared containing a physiologically-active component that 25- augments the oxygen-transport capability of the body, to treat various anemias, and act as an oxygen-carrying plasma volume expander. Initially, three aqueous solutions are prepared: an aqueous solution including at least about 0.1%, e.g. .1 to 5% w/v of a first non-toxic surfactant, such as albumin; optionally an aqueous solution including at least about 0.1%, e.g.
.1 to 5% w/v of a second surfactant, such as lecithin;
and a aqueous solution containing an oxygen-carrying molecule containing iron, such as heme, a hemoprotein and/or a heme-hemoprotein complex. It is preferred that the hemoprotein of the heme-hemoprotein complex be stroma-free hemoglobin.

~. , . ^ - , , -96- 13~,~r ~ , In accordance with still another important embodiment of the present invention, it has been found that the instability of the physiologically-active iron-containing molecule capable of carrying and re-leasing oxygen (heme and/or the hemoproteins and/or the heme-hemoprotein complex) can be minimized or substantially completely eliminated by treating a solution ~preferably aqueous) containing the iron-containing molecule, prior to coacervation, with a chemical complexing agent capable of forming a stable iron complex, such as carbon monoxide or an inorganic cyanide, particularly cyanide salts or cyanide complex-es, such as sodium cyanide or hydrogen cyanide, and thereafter treating the complexed solution, preferably to saturation, with an interactant, capable of interac-tion with the iron complex, to release the complexing agent from the iron-containing molecule which escapes from the solution in gaseous form. To achieve the full advantage of the present invention, the chemical complexing agent is carbon monoxide and the interactant is oxygen or purified air bubbled through the solution in excess to release the carbon monoxide from the iron-containing molecule and saturate the solution to remove the carbon monoxide from the solution. This process of iron-complexing and then interaction to release the complexing molecule will stabilized the physiologically-active iron-containing solution, either before or after admixture or emulsification with the other components of the composition so long as the process is carried out prior to coacervation. To achieve full advantage of the present invention, an antioxidant, such as ascorbic acid, is added to the final composition to prevent oxidation of the final composition.
In general, the amount of heme and/or hemo-protein, and/or heme-hemoprotein complex present in the composition of the present invention is determined -97- ~ 1~21~
by the clinically indicated required dose for the treatment of a particular dysfunction. If the composi-tion is to be used to augment the oxygen-carrying capacity of the recipient, the amount of heme, hemo-S protein and/or heme-hemoprotein complex in the composi-tion of the present invention is the amount necessary to restore oxygen transport to normal levels within the time frame of the treatment regimen. However, if the intended use of the composition of the present invention is to treat anemic states, such as those due to blood loss, the quantity of heme, hemoprotein and/or heme-hemoprotein complex is the amount necessary to restore normal hemoglobin levels of between approx-imately 5% and approximately 14% within the time frame lS of the treatment regimen. Likewise, if the intended use of the composition of the present invention is to treat iron deficiency states, an exemplary amount of heme, hemoprotein and/or heme-hemoprotein complex is that amount that introduces approximately 100-150 mg of elemental iron per dose.
In accordance with the preferred embodiment, the aqueous albumin, lecithin and heme, hemoprotein and/or heme-hemoprotein complex solutions then are thoroughly admixed. Alternatively, the powdered forms of albumin, lecithin, and the heme, hemoprotein and/or heme-hemoprotein complex can be admixed, then converted into a solution by adding sufficient water such that the amount of albumin and lecithin each equals approx-imately 3% w/v in the finished composition, and the heme, hemoprotein or heme-hemoprotein equals from about 5% to about 30% w/v in the finished composition.
This mixture then is subjected to a physical or chemi-cal precipitating agent. For example, heat, ranging from about 20 to about 70 C., is applied until the mixture ~precipitates" to produce an aqueous two-phase coacervate system. Temperatures below about 20 C., or above about 70 C., can be utilized accord-:, .

-98- 1 321.r~
ing to the method of the present invention so long as the time of heat treatment causes the solution to precipitate into a two-phase coacervate solution while preventing excessive heat treatment to the extent of S denaturing the composition causing loss of the coacer-vate. Alternatively, rather than heating, a non-toxic alcohol, such as ethyl alcohol, or an appro-priate electrolyte, such as sodium chloride, can be added to the mixture to produce an aqueous, two-phase coacervate system. The coacervate system then is emulsified using conventional techniques. The isoton-icity and the pH of the emulsion are adjusted to ap-proximate the values found in the human body, approxi-mately O.g~ saline. The pH is adjusted using an acid, lS such as hydrochloric acid, or an alkaline substance, such as sodium hydroxide. Isotonicity is adjusted through addition of an appropriate electrolyte such as sodium chloride, or water as required.
This emulsion can be used as a composition for the oral or intravenous introduction of iron into the body. However, the optional addition of a sterol, such as cholesterol, added in a sufficient amount, for example from about 1% to about 5g w/v based on ~ the total weight of both phases, provides the composi-tion with a degree of surface hardness thereby improv-ing the composition for use as an orally or intraven-ously administrable composition.
The emulsion also can be processed further, before isotonicity and pH adjustments are made, by using conventional techniques to produce a microemul-sion. The microemulsion includes the coacervate-based microemulsified particles and the heme, and/or hemoprotein and/or the heme-hemoprotein complex, each in a form that is compatible with the recticuloendo-thelial system and microcirculation systems of the human body and is a size that can be absorbed by the -99- 132~5~2 intestines. This microemulsion composition can be administered orally or intravenously.
For oral administration, the microemulsion can be dispensed by any of the conventional oral dosage forms, such as liquid microemulsion or soft capsula-tion, e.g. a syrup or a capsule containing a liquid.
In accordance with another important feature of the present invention, the microemulsion can be processed further using either heat or a cross-linking agent to produce a microencapsulated composition having sus-tained time-release characteristics. Generally, heat, ranging from 25 to 70 C., is preferred, and is applied over varying time periods, such as about 2 sec. to about 150 sec., to convert the microemulsion into microencapsulated particles having varying degrees of surface-coacervate film hardnesses. The micro-emulsified coacervate can also be treated at tempera-tures about 70 C., or below 25 C., for a time suffi-cient to produce a time-release composition capable of releasing the physiologically-active component, for example, up to about 72 hours, after administration of the composition. It has been found that longer heating time increases the fiIm hardness, thereby affecting the time-release characteristics of micro-encapsulated particles. Therefore, particles of simi-lar or different release rates can be combined in a single dose and can be administered orally or intra-venously after being placed in an appropriate vehicle or dosage form.
In accordance with the present invention, coacervate systems also can bé produced by using a - single surfactant, such as albumin alone, and a pre-cipitating agent. The precipitating agent can be a non-toxic alcohol, such as isopropyl alcohol or n-butyl alcohol, electrolytes, heat, or a combination thereof. Similarly, an alternative coacervate system that can be used in the compositions of the present . , -loo- - 1 3 2 1 ~
invention, can be manufactured by preparing an aqueous solution of a surfactant, such as lecithin, and then adding a precipitating agent, such as an alcohol or an electrolyte in sufficient amount for phase separa-tion to to yield a coacervate system. Subsequentprocessing steps for these alternative coacervates to produce orally or intravenously administrable micro-emulsified or microencapsulated compositions are iden-tical to the processing steps described above.
Specific examples directed to the coacervate compositions including an iron-containing molecule capable of carrying and releasing oxygen (heme and/or hemoproteins and/or heme-hemoprotein complexes) are provided in the following examples 161-175.

An aqueous 3% w/v solution of albumin, an aqueous 3% w/v solution of lecithin and an aqueous solution of heme, containing the dose of heme desired in the end product, are thoroughly admixed after the heme solution was treated with sufficient carbon mon-oxide to drive off essentially all the oxygen. The mixture then is heated at 50 C. for a sufficient time to produce a two-phase coacervate system. The two-phase coacervate system then is emulsified in a blender, followed by the addition of an antioxidant, such as ascorbic acid, and by adjustment of (1) isoton-icity using sodium chloride and/or water and (2) pH
using either an acid or a base, such as hydrochloric acid or sodium hydroxide in an amount sufficient to bring the isotonicity and pH values of the emulsion within normal physiological ranges, e.g., 7.2 to 7.5 pH. The emulsion then is converted, by conventional colloid mill techniques to a microemulsion of coacer-vate-based microemulsified particles, having a diameter of approximately 1 micron or less. The composition containing the microemulsified particles, containing encapsulated heme, then is adjusted for isotonicity -101- ~ 3~r and pH as above, if necessary. The microemulsified particles can be used for oral or intravenous adminis-tration to the body. This microemulsified composition then is heated at 60 C. for about 2 to about 150 seconds to produce hardened, microencapsulated parti-cles having a range of sustained time-release charac-teristics. The microencapsulated particles then are treated with excess oxygen to remove the carbon monoxide, and, optionally, stored under an inert blanket of nitrogen gas. These hardened, microencap-sulated particles, when added to a suitable vehicle, such as syrup, also can be used orally, or in a physio-logical saline solution intravenously. These composi-tions are useful to augment the oxygen-transport capa-city of the recipient and to increase circulatory volume.

The procedure of Example 129, except that a complex of heme and stroma-free hemoglobin replaced the heme.

The procedure of Example 129, except that an aqueous solution of 3% w/v of casein replaced the aqueous 3% w/v solution of albumin.

The procedure of Example 129, except that an aqueous 3% w/v solution of gelatin replaced the aqueous 3% w/v solution of albumin.

The procedure of Example 129, however the manufacturing process was terminated after preparation of the coacervate system microemulsion, thereby pro-ducing an orally administrable composition useful in the treatment of iron deficiency anemia, and anemias due to blood loss.

-102- 1 3 ~

The procedure of Example 133, except that a heme and stroma-free hemoglobin complex replaced the heme, thereby producing a composition useful in treat-ing anemias due to iron deficiency or blood loss.

The procedure of Example 129, except that the preparation of the microencapsulated sustained time-release formulation is omitted.

The procedure of Example 129, except that the complex of heme and stroma-free hemoglobin is used, and the manufacturing process is terminated after preparation of the microemulsion.

The procedure of Example 1291 except that an aqueous 5% w/v solution of albumin is used instead of the aqueous 3~ w/v albumin solution.

-The procedure of Example 129, except that an aqueous 4% w/v solution of lecithin is used instead of the aqueous 3% w/v lecithin solution.

-The procedure of Example 129, except that the coacervate system is produced by subjecting an aqueous 3% w/v solution of albumin to temperatures of 30-3S C. until formation of a two-phase coacervate system.

The procedure of Example 129, except that the coacervate system is prepared by the dropwise addition of ethyl alcohol to to an aqueous 3~ w/v solution of lecithin until a two-phase coacervate system is produced.

The procedure of Example 129, except that an aqueous 3~ w/v solution of casein is used to replace -103- 132~ ~ll2 the aqueous 3~ w/v albumin solution, and a complex of heme and stroma-free hemoglobin is used to replace the heme.

The procedure of Example 129, except the heme molecule is first encapsulated in a lecithin-cased liposome before proceeding to produce the aqueous two-phase coacervate system.

The procedure of Example 129, except the heme-hemoglobin complex is first encapsulated in a lecithin-cased liposome before proceeding to produce the aqueous two-phase coacervate system.
According to the perhalogenated embodiment of the method and composition of the present invention, a non-toxic perhalogenated compound, such as a per-fluorinated hydrocarbon and/or a perfluorinated amine, can be used with the aqueous coacervate system to provide the compositions of the present invention.
The perhalogenated compounds useful in the present invention include perfluorinated and perfluoriodinated aliphatic and alicyclic hydrocarbons, perfluorinated and perfluoriodinated aliphatic and alicyclic ethers, and/or perfluorinated and perfluoriodinated aliphatic and alicyclic amines. It has been found that per-fluorodecalin and perfluoroiododecalin are especially useful in the compositions of the present invention, either used alone or in combination with other per-fluorinated compounds, such as perfluorotributylamine, perfluorotripropylamine, perfluorotrimethylbi-cyclo[3.3.1]nonane and/or perfluoro-N,N-dimethylcyclo-hexylmethylamine.
In accordance with an important feature of the present invention, a method of producing a composi-tion, including a perhalogenated, and preferably a perfluorinated, compound; a two-phase aqueous coacer-vate system; and a physiologically-active compound is ... . . .

-104- 1 ~ 2 ~
disclosed. According to the method of the present invention, the physiologically-active compound is admixed with the perhalogenated compound, and the resulting mixture then is admixed with an aqueous S surfactant solution, such as an aqueous albumin solu-tion and/or an aqueous lecithin solution. Subsequent processing of the complete mixture produces a coacer-vate system. The resulting coacervate-based composi-tion then is processed further to produce a microemul-sion, having particles of 1 micron or less in diameter.Additionally, the microemulsion can be processed fur-ther using heat, or other appropriate precipitating agents, to produce sustained time-release compositions, having a single rate of release or a range of release rates.
Tne composition of the present invention can be administered orally or parenterally, preferably intravenously. In addition, the composition of the present invention can be lyophilized using conventional techniques to convert the liquid to a powder. The powdered product then can be reconstituted using appro-priate physiological fluids. For instance, when the reconstituted composition is intended for intravenous use, isotonicity and pH should be adjusted to normal body values before administration.
In preparing the compositions of the present invention, it is preferred that both phases of the two-phase, aqueous coacervate system be used. However, the non-polar, colloid-rich phase can be separated from the colloid-poor phase, then used to prepare the compositions of the present invention. The composi-tions of the present invention comprise microemulsified particles containing the aqueous coacervate and the perhalogenated compound. A physiologically-active component can be incorporated into the perhalogenated compound-coacervate system compositions of the present invention to yield a variety of end products that are -105- 1~21~
useful in the medlcal field. The microemulsified particles are manufactured to be of appropriate size, such that the particles are compatible with the micro-circulation system and the reticuloendothelial system S of the human body and other mammals. The compositions of the present invention may, if desired, be processed further to produce compositions having time-release characteristics, such as by microencapsulating the particles to provide a time-release hardened coating on the composition.
To prepare the perhalogenated compositions embodiment of the present invention, two solutions are prepared: an aqueous solution, including from about 0.01% w/v to a quantity up to about 100% w/v dispersion, of albumin; and an aqueous solution includ-ing from about 0.01% w/v to a quantity up to about 100% w/v dispersion of lecithin. In addition, a suffi-cient amount of a perhalogenated compound, such as perfluorodecalin, is required to produce a composition including from about 0.1% w/v to about 99~ w/v of the perhalogenated compound. To achieve the full advantage of the present invention, the aqueous solutions include from about 1% to about 5%, and preferably about 3~, w/v of albumin and about 1% to about 5%, and preferably about 3% w/v of lecithin. Optionally, powdered albumin and/or powdered lecithin can be mixed with the perhalo-genated compound, and this mixture then converted to an aqueous solution containing the required amount of albumin, lecithin and perhalongenated compound. Ac-cording to the method of the present invention, thecompositions can include equal or unequal proportions of albumin solution to lecithin solution, however, equal proportions of the albumin and lecithin solutions are preferred. To achieve the full advantage of the present invention, equal weight amounts of albumin and lecithin are included in the compositions of the present invention.

-106- - 13~ 2 For example, if the finished product is intended to be used as a barrier to food absorption, approximately equal amounts of an approximately 3%
w/v aqueous solution of albumin and an approximately 3% w/v aqueous solution of lecithin, and a quantity of a perhalogenated compound, such as perfluorodecalin, are thoroughly admixed and processed in a colloid mill to yield a mixture including from about 30~ w/v to about 50% w/v, and preferably about 40% w/v, of perfluorodecalin. The mixture then is subjected to a physical or chemical precipitating agent. For example, heat, ranging from about 20 to about 70 C., and preferably ranging from about 30 to about ~0 C, is applied until the mixture "precipitates" to produce a composition comprising the aqueous two-phase coacervate system and the perhalogenated compound. Temperatures below about 20 C., or above about 70 C., can be utilized according to the method of the present inven-tion so long as the time of heat treatment causes the solution to precipitate into a two-phase coacervate solution while preventing excessive heat treatment to the extent of denaturing the composition causing loss of the coacervate. Alternatively, rather than heating, a non-toxic alcohol, such as ethyl alcohol, or an appropriate electrolyte, such as sodium chloride, can be added to the mixture to produce an aqueous, two-phase coacervate system. The mixture is subjected to the physical or chemical precipitating agent until visual inspection, or inspection by microscopic tech-niques known to those skilled in the art, shows thatthe mixture has separated into the two-phase aqueous coacervate system.
The coacervate system-perhalogenated compound composition then is re-emulsified using conventional techniques. The resulting emulsion also can be pro-cessed further, by using conventional techniques, such as a colloid mill to produce a microemulsion.

-107- 13 2~ `t, The microemulsion includes the coacervate-based micro-emulsified particles and the perfluorinated compound, each in a form that is compatible with the recticulo-endothelial system and microcirculation systems of the human body. ThiS microemulsion composition can be administered orally or intravenously.
For oral administration, the microemulsion can be dispensed by any of the conventional oral dosage forms, such as liquid microemulsion or soft capsula-tion, e.g. a syrup or a capsule containing a liquid.In accordance with another important feature of the present invention, the microemulsion can be processed further using either heat or a cross-linking agent to produce a microencapsulated composition having sus-tained time-release characteristics. Generally, heat, ranging from 25 to 70 C., is preferred, and is applied over varying time periods, such as about 2 sec. to about 150 sec., to convert the microemulsion into microencapsulated particles having varying degrees of surface-coacervate film hardnesses. The micro-emulsified coacervate can also be treated at tempera-tures above 70 C., or below 25 C., for a time suffi-cient to produce a time-release composition capable o~ releasing the physiologically-active component, for example, up to about 72 hours, after administration of the composition. It has been found that longer heating time increases the film hardness, thereby affecting the time-release characteristics of micro-encapsulated particles. Therefore, particles of simi-lar or different release rates can be combined in asingle dose and can be administered orally or intra-venously after being placed in an appropriate vehicle or dosage form.
The composition made in accordance with the above method can be utilized in weight reduction pro-grams, whereby after orally administering the food-barrier composition, the perhalogenated compound in--108- 1 3 2~lî"
cluded in the composition coats the intestinal walls to preclude the absorption of food. Therefore, the patient is not limited in the amount of food consumed because no Eood is absorbed through the intestinal walls until the perhalogenated compound is expelled ~rom the body. The dosages and fre~uency of treatment are clinical determinations that are made in regard to each individual patient such that weight loss objec-tives and nutritional needs are balanced.
It should be noted that other additives, such as flavorants, can be added to the perhalogenated compound-aqueous coacervate composition to enhance patient appeal, without detracting from the efficacy of the composition. According to the method of the present invention, the aqueous coacervate system allows the oral introduction of the non-polar, non-aqueous perhalogenated compound into the patient without the need of additional emulsifying and suspending agents that are normally required to solubilize the perfluor-inated compound, but generally detract from productaesthetics and patient appeal.
The aqueous coacervate system, including the perfluorinated compound, can also be used as a resuscitation fluid to quickly introduce an oxygen-carrying molecule into a patient. In the manufactureof a resuscitation fluid, the process of admixing the aqueous albumin and lecithin solutions and the per-fluorodecalin is performed as above except that prior to admixing the three liquids heme and/or stroma-free hemoglobin, in an amount ranging from about 0.1% to about 30% w/v is added to the perfluorodecalin The amount of perhalogenated compound used in the resusci-tation fluid is limited to from abut 10% w/v to about 30~ w/v, and preferably to about 20% w/v, of the entire composition. At these levels, the amount of perhalo-genated compound is too low to act as a food barrier, but is sufficiently large to coat the intestinal wall -109- l ~
and bring the heme and/or stroma-free hemoglobin into intimate contact with the intestinal wall for rapid absorption. The perhalogenated compound is not ab-sorbed by the intestinal walls but serves to facilitate transport of the oxygen-carrying heme or stroma-free hemoglobin into the circulatory system.
It is preferred that the amount of the oxy-gen-carrying molecule included in the resuscitation fluid approximate the amount of hemoglobin percent in whole blood, such as from about 5% to about 14%. It should be noted, however, that because of the inherent oxygen-carrying capability of the perfluorinated com-pound, the amount of heme or stroma-free hemoglobin can be below the 14% wt~ hemoglobin normally found in whole bloodO The heme or hemoglobin used in the pre-sent invention may be of endogenous, exogenous, or synthetic sources.
After admixing the albumin and lecithin solutions, the perhalogenated compound, and the heme and/or stroma-free hemoglobin, the osmotic pressure of the resulting mixture is adjusted to the isotonicity of whole blood by the addition of sodium chloride and/or any other suitable electrolyte or water, as required. The pH is adjusted using an acid, such as hydrochloric acid, or an alkaline substance~ such as sodium hydroxide. The isotonicity and the pH of the emulsion are adjusted to approximate the values found in the human body, approximately 0.9~ saline, and a pH of approximateIy 7.3 to 7.45.
After the pH and isotonicity adjustments, the mixture is processed as previously described for the food-barrier composition to produce a microemulsion having a particle size that is compatible with the microcirculation and the reticuloendothelial system, such as 1 micron or less in diameter. The product then can be administered intravenously as a resuscita-tive fluid.

-llo- ~ 1~2~2 Similarly, a product use~ul as an oxygen-carrying contrast medium, such as those used in angio-scopy, can be manufactured according to the method of the present invention. The oxygen-carrying contrast medium can be prepared by the method described above for the manufacture of a resuscitation fluid, however, a perfluoroiodinated compound, such as perfluoroiodo-decalin or iodinated perfluorodecalin, is used in place of perfluorodecalin.
If the perfluorinated compound-coacervate system composition is to be used as a drug delivery system, perfluorodecalin, the albumin solution and the lecithin solution are prepared as described above.
Before the solutions are admixed, however, the non-polar to semi-polar physiologically-active and/or pharmacological compound or compounds are admixed into the perfluorodecalin in a sufficient amount to yield the desired, or required, dose in the finished product. If the solubility of the physiologically-active and/or pharmacological compound or compounds in the perfluorinated compound is exceeded, the phy-siologically-active and/or the pharmacological compound or compounds can be dispersed and suspended in the perfluorinated compound to achieve the required, or desired, clinical dosage.
The physiologically-active and/or pharmacolo-gical components can include any drug, hormone, bio-logical, enzyme, antibiotic, peptide or other useful medical composition that is soluble in the perfluorin-ated compound to a sufficient degree to obtain a clini-cal dose. If salts of the parent drug compounds or other water-soluble pharmaceuticals also are included in the product, these compounds are dissolved in the aqueous albumin or the aqueous lecithin solutions before admixing and processing to produce the coacer-vate system. After admixing, the mixture is processed 132~

in the same manner as described previously to prepare the food barrier composition.
In those instances where the product is to be administered intravenously, the p~ and isotonicity of the composition are adjusted, if necessary, to approximate that of whole blood. The product then is suitable for either oral or intravenous administration, as the particle size of the microemulsion, 1 micron or less in diameter, allows absorption through the intestinal wall and is compatible with the microcircu-lation system and the reticuloendothelial system.
For oral compositions, the amount of the perhalogenated compound is maintained at between about 10% w/v to about 30% w/v, and preferably about 20% w/v of the finishèd drug composition to facilitate absorption of the drug into the circulatory system. For parenterally administered compositions, the amount of perhalogenated compound can be incorporated in amounts varying from about 0.1% w/v to about 99% w/v of the finished drug composition, in order to maximize the solubility and stability of the physiologically-active and/or pharma-cological component.
The method of the present invention also can be utilized to incorporate a local or general anesthetic into the coacervate system-perhalogenated compound composition. The anesthetic agent, either a gas, liquid, liquified gas, or mixture thereof, first is dissolved in the perfluorinated compound in the amount necessary to produce the desired anesthetic dose in the final product. As described previously, the albumin solution, lecithin solution and perfluorin-ated compound are admixed, followed by heating the mixture at temperatures ranging from approximately 20 to approximately 70 C for a sufficient time to produce a two-phase coacervate system, as shown by visual or microscopic techniques.

The two-phase coacervate syste~ then is processed to yield a microemulsion, having a particle size that is compatible with the microcirculation and the reticuloendothelial system. The pH of the micro-S emulsion is adjusted to that of whole blood using anacid, such as hydrochloric acid or a base such as sodium hydroxide. The resulting product is suitable for intravenous and/or oral administration, allo~ing for more control in the amount of anesthetic delivered and in the depth of the anesthesia.
Any of the oral or intravenously administered products can be prepared in a sustained time-release form by treating the composition with an organic alde-hyde, such as glutaraldehyde, or heat. The method provides a composition having a single or multiple rate of release. The process yields microemulsified particles encapsulated by a coacervate-based film that can be of any desired degree of particle surface film hardness, ranging from liquid to gel-like to rigid.
According to this method, a portion, or all, of the microemulsified composition is heated, generally in a range of from about 25 to about 70 C, and preferably in the range of 30 to about 40 C
over a varying time period, such as 2 sec. to about 150 sec., to convert the microemulsion into microen-capsulated particles having varying degrees of coacer-vate film hardness. The microemulsified coacervate can also be treated at temperatures above 70 C., or below 25 C., for a time sufficient to produce a time-release composition capable of releasing the physiolo-gically-active component, for example, up to about 72 hours, after administration of the composition. It has been found that longer heating time increases the film hardness, thereby affecting the time-release characteristics of microencapsulated particles. There-fore, particles of similar or different release rates -113- 13~
can be combined in a single dose and can be adminis-tered orally or intravenously after being placed in an appropriate vehicle or dosage form.
In accordance with the present invention, coacervate systems also can be produced by using a single surfactant, such as albumin alone, and a pre-cipitating agent. The precipitating agent can be a non-toxic alcohol, such as isopropyl alcohol or n-butyl alcohol; electrolytes; heat; or a combination thereof. Similarly, an alternative coacervate system that is useful in the compositions of the present invention, can be manufactured by preparing an aqueous solution of a surfactant, such as lecithin, and then adding a precipitating agent, such as an alcohol or an electrolyte, in sufficient amount for phase separa-tion to yield a coacervate system. Subsequent process-ing steps for these alternative coacervates to produce orally or intravenously administrable microemulsified or microencapsulated compositions are identical to the processing steps described above.
~pecific examples of the perhalogenated composition embodiment of the present invention are provided in the following examples 144-180.

Approximately equal volumes of an aqueous 3% w/v solution of albumin and an aqueous 3% w/v solu-tion of lecithin, and a sufficient amount of perfluoro-decalin to provide 40% w/v of perfluorodecalin in the final solution are thoroughly admixed. The mixture then is heated at 70 C. for a sufficient time, such as from about 3 seconds to about 2 minutes, to produce a two-phase coacervate system. The mixture is examined continuously by visual or microscopic techniques throughout the heating period in order to terminate the application of heat as soon as the mixture separ-ates into a two-phase aqueous coacervate system. The coacervate system, including the perfluorodecalin, 13~5~

then is processed in a colloid mill to produce a micro-emulsion. The microemulsion then can be used as an orally-administrable food absorption barrier composi-tion.

The procedure of Example 144, except that the application of heat is replaced by the dropwise addition of ethyl alcohol until a visual inspection shows that the mixture has separated into the two-phase aqueous coacervate system.

The procedure of Example 144, except that the application of heat is replaced by the addition of sodium chloride until a visual inspection shows that the mixture has separated into the two-phase aqueous coacervate system.

The procedure of Example 144, except that perfluorotributylamine is used in place of perfluoro-decalin to yield a food absorption barrier composition including 30~ w/v or perfluorotributylamine.

The procedure of Example 144, except that the same volume of an aqueous 5~ w/v albumin solution is used.

The procedure of Example 144, except that the same volume of an aqueous 5~ w/v lecithin solution is used.

The procedure of Example 144, except that the mixture is heated at 40 C.

The procedure of Example 144, except that an aqueous solution of heme is admixed into the per-fluorodecalin before the albumin solution, lecithin solution and perfluorodecalin are thoroughly admixed.

-115- ~ Lr'~
The amount of 20% w/v heme solution added to the mix-ture is sufficient to provide a final composition including approximately 7~ w~v of heme. The perfluoro-decalin is present at approximately 20% w~v of the final composition. The isotonicity and pH of the mixture then are adjusted using sodium chloride and/or water, and either an acid or a base, such as hydro-chloric acid or sodium hydroxide, in an amount suffi-cient to bring the isotonicity and pH values of the emulsion within normal physiological ranges, e.g., 7.2 to 7.5 pH and 0.9~ saline. The mixture then is heated at approximately 70 C until a visual inspection indicates that the mixture has separated into the two-phase aqueous coacervate system. The coacervate system, including the heme, then is emulisifed to produce a microemulsion having a particle size of 1 micron or less in diameter. The composition then can be used as an intravenously administrable resuscitation fluid.
EXA~PLE 152 The procedure of Example 151, except that an aqueous solution of 20% w/v stroma-free hemoglobin instead of heme is admixed into the aqueous 3% w/v albumin solution to provide a mixture including 7%
stroma-free hemoglobin.

The procedure of Example 151, except that an à~ueous solution of a heme and stroma-free hemoglo-bin complex instead of heme is admixed into the aqueous 3% w/v lecithin solution to provide a mixture including 7% w/v heme and stroma-free hemoglobin complex.

The procedure of Example 152, except that polymerized stroma-free hemoglobin is used in place of heme.

EXAMPLE 155 13 2 ~
The procedure of Example 152, except that pyridoxilated polymerized, stroma-free hemoglobin is used in place of heme.

The procedure of Example 151, except that the composition includes 30% w/v of perfluorinated trimethylbicyclo[3.3.1]nonane in place of the 20 perfluorodecalin~

The procedure of Example 151, except that the composition includes 20% w/v of perfluorotributyl-amine in place of the 20% perfluorodecalin.

The procedure of Example 151, except that the composition includes 12% w/v of perfluorodecalin and 8% w/v of perfluorotributylamine in place of the 20~ perfluorodecalin.

The procedure of Example 151, except that insulin is used in place of heme to provide a composi-tion including 40 units/cc of insulin.

The procedure of Example 151, except that the an~i-coagulant, sodium heparin, is used in place of heme to provide a composition including 1000 USP
units/ml of sodium heparin.
EXAMPLE 1~1 The procedure of Example 144, except (1) methotrexate, a cancer treatment drug, is added to the perfluorodecalin before the perfluorodecalin is admixed with the aqueous lecithin and aqueous albumin solutions, and (2) the pH of the albumin-lecithin-perfluorodecalin-methotrexate mixture is adjusted to approximately 7.4, by adding either hydrochloric acid or sodium hydroxide, before the mixture is processed -117- ~ u~
to produce a microemulsion to provide a composition including 25 mg~ml of methotrexate.

The procedure of Example 161, except (1) S the antibiotic, gentamycin, is used in place of metho-trexate, and (2) the pH adjustment is made after the mixture is processed to produce a microemulsion to provide a composition including one mg/ml of genta-mycin.
ExAMPLE 163 The procedure of Example 161, except (1) the antibiotic, cefazolin, is used in place of metho-trexate, and (2) the pH adjustment is made before and after the mixture is processed to produce a microemul-lS sion to provide a composition including 125 mg/ml ofcefazolin.

The procedure of Example 161, except that the antibiotic cephapirin is used in place of metho-trexate to provide a composition including 250 mg/mlof cephapirin.

The procedure of Example 161, except that the antibiotic thiopental is used in place of metho-trexate.

The procedure of Example 161, except (1~the anesthetic halothane is used in place of methotrex-ane, and (2) the halothane is bubbled into the per-fluorodecalin to provide a composition including 20%w/v of halothane.

The procedure of Example 161, except thatthe anesthetic fentanyl is used in place of methotrex-ate to provide a composition including 0.05 mg/ml offentanyl.

-118- 1 ~ 2~L!, The procedure of Example 161, except that the anesthetic sufentanil is used in place of metho-trexate to provide a composition including 50 ug/ml of sufentanil.

The procedure of Example 161, except that the muscle relaxant succinylcholine is used in place of methotrexate to provide a composition including 20 mg/ml of succinylcholine.

The procedure of Example 161, except that calcitonin, used in the treatment of osteoporosis, is used in place of methotrexate to provide a composition including 20 I.U./ml of calcitonin.

The procedure of Example 161, except that the anesthetic ketamine is used in place of methotrex-ate to provide a composition including 10 mg/ml of ketamine.

The procedure of Example 161, except that the anesthetic fluorocil is used in place of metho-trexate to provide a composition including 50 mg/ml f fluorocil.

The procedure of Example 161, except that the labor inducer oxytocin is used in place of metho-trexate to provide a composition including 10 USP
units/ml of oxytocin.

The procedure of Example 151, except that monensin is used in place of heme.

The procedure of Example 161, except that monensin is used in addition to methotrexate to provide a composition including 25 mg/ml of methotrexate.

EXAMPLE 176 ~ ~ 2 ~
The procedure of Example 144, except that iodine is added to the perfluorodecalin prior to the admixing the albumin solution, lecithin solution and perfluorodecalin solution to provide a contrast medium containing 1% w/v of iodine.

The procedure of Example 144, except that vitamin A, vitamin D, and vitamin E are added to the 10 perfluorodecalin prior to admixing the perfluoro-decalin, albumin solution and lecithin solution. After admixing, the mixture is heated at 70 C until the mixture separates into a two-phase coacervate system.
The two phases are separated, and thiamine hydro-15 chloride, d-biotin, riboflavin, niacinamide, pyridoxine hydrochloride, dexpanthenol, ascorbic acid, folic acid, and cyanocobalamin is added to the polar phase.
The phases are recombined and processed to produce a microemulsion having a particle size of 1 micron or 20 less in diameter to provide a composition including 3300 USP units/ml of vitamin A, 200 USP units/ml vita-min D, 10 USP units/ml vitamin E, 3 mg/ml thiamine hydrochloride, 60 mg/ml d-biotin, 3.5 mg/ml riboflavin, 40 mg/ml niacinamide, 4 mg/ml pyridoxine hydrochloride, 25 15 mg/ml dexpanthenol, 100 mg/ml ascorbic acid, 400 ug/ml folic acid, and S ug/ml cyanocobalamin.

The procedure of Example 161, except that the anti-asthmatic aminophylin is used in place of - methotrexate to provide a composition including 25 mg/ml of aminophylin.

The procedure of Example 153, except that the microemulsion is divided into four equal portions.
The first portion is left untreated, the second portion is heated at 70 C for 10 seconds, the third portion is heated at 70 C for 40 seconds and the fourth por--120- lC?~ r' ~ .
tion is heated at 70 C for 70 seconds to produce a microencapsulated composition having sustained time release capabilities.

The procedure of Example 144, except that the commercial product, perfluoroiodide, is used in place of perfluorodecalin to provide a contrast medium including 40% w/v of perfluoroiodide.
It will be understood that the present dis-closure has been made only by way of preferred embodi-ment and that numerous changes in details of construc-tion, combination, and arrangement of parts can be resorted to without departing from the spirit and scope of the invention as hereunder claimed.
lS What is claimed and sought to be secured by Letters Patent of the United States is:

Claims (45)

1. A method of preparing a composition useful as a system to introduce and transport medically useful compositions in the body of mammals;
said composition comprising particles of a coacervate-based matrix having one or more physiologically-active compound incorporated therein and a coacervative-based encapsulating film surrounding each particle;
said method comprising forming a mixture of one or more surface active agents, water and one or more physiologically-active compounds to produce a two phase aqueous coacervate composition containing said compound, and emulsifying the composition to produce an aqueous emulsion of coacervate-based matrix particles containing the physiologically-active compound, said coacervate-based matrix comprising water selected from the group consisting of coacervate phase water, equilibrium phase water, and mixtures thereof, and said physiologically-active compound solubilized therein, said particles having an encapsulating coacervate-based film surrounding the particles.

2. The method of claim 1 further including adding an organic solvent to the mixture to form the two phase coacervate composition.

3. The method of claim 2, wherein the organic solvent comprises N-butyl alcohol or a glyceride.

4. The method of claim 1, wherein the surface active agents comprise a composition of a surface active protein and a surface active phospholipid.

5. A method of preparing a composition containing one or more physiologically-active compounds for oral, inhalation, tissue absorptive or parenteral administration to a mammal comprising emulsifying an aqueous solution of water, a polymerized or polymerizable surface active agent, a coacervating agent and a physiologically-active compound to form an aqueous emulsion of coacervate-based matrix particles containing the physiologically-active compound solubilized therein, and bound in the coacervate matrix within a coacervate-based aqueous film containing the polymerized surface active agent wherein said coacervate matrix comprises water selected from the group consisting of coacervate phase water, equilibrium phase water, and mixtures thereof, and said physiologically-active compound solubilized therein.

6. The method of claim 5, further including emulsifying and microemulsifying the composition to form coacervate particles useful for oral administration having a particle size less than about 800 microns.

7. The method of claim 5, wherein the coacervate particles are microemulsified to less than about 1 micron.

8. The method of claim 5, wherein the surface active agent is a polymerized phospholipid.

9. The method of claim 8, wherein the polymerized phospholipid is polymerized lecithin.

10. The method of claim 8, wherein the phospholipid is selected from the group consisting of lecithin, cephalin, isolecithin, sphingomyelin, phosphatidyl serine, phosphatidic acid, phosphatidyl inositol, phosphatidyl choline, and mixtures thereof.

11. The method of claim 5, wherein the coacervate system includes two surface active agents, at least one of which is a polymer having a molecular weight of 300,000 or less.

12. The method of claim 11, wherein the two surface active agents comprise a phospholipid and a surface active protein.

13. The method of claim 12, wherein the two surface active agents comprise lecithin and polymerized albumin.

14. The method of claim 5, further including drying the composition to form a powder capable of being reconstituted by the addition of a physiologically acceptable liquid.

15. The method of claim 5, wherein the surface active agent is added in monometric form and further including adding a polymerization initiator to said composition, said polymerization initiator capable of and in an amount sufficient to polymerize the surface active agent during processing of said composition.

16. The method of claim 15, wherein the polymerization initiator is l-ethyl-3-dimethyl-aminopropylcarbodiimide.

17. The method of claim 5, wherein the physiologically-active compound is a peptide.

18. The method of claim 17, wherein the physiologically-active compound is a polypeptide.

19. The method of claim 5, including admixing with the coacervate composition a glyceride selected from the group consisting of a monoglyceride, a diglyceride, a triglyceride, and mixtures thereof; said physiologically-active compound being dissolved or dispersed in the glyceride; said aqueous coacervate-based matrix particles encapsulated in a coacervate-based film encapsulating the glyceride and the physiologically-active compound within the coacervate-based matrix particles, said coacervate-based matrix particles comprising water selected from the group consisting of coacervate phase water, equilibrium phase water, and mixtures thereof, the glyceride, and the physiologically-active compound dissolved or dispersed within the matrix particles.

20. The method of claim 19, wherein the glyceride is a triglyceride having 8 to 18 carbon atoms per each substituted acid chain.

21. A use for introducing a physiologically-active compound into the circulatory system of a mammal of a composition comprising an aqueous coacervate system including water and a surface active agent, said coacervate system including an aqueous emulsion of coacervate-based matrix particles containing the compound solubilized therein; said aqueous coacervate-based matrix comprising water selected from the group consisting of coacervate phase water, equilibrium phase water, and mixtures thereof, and said physiologically-active compound solubilized therein.

22. The use of claim 21, wherein the surface active agent comprises a protein, polymerized protein, phospholipid, polymerized phospholipid, or mixtures thereof.

23. The use of claim 22, wherein the polymerized protein is polymerized albumin.

24. The use of claim 22, wherein the polymerized phospholipid is a polymer of a compound selected from the group consisting of lecithin, cephalin, isolecithin, sphingomyelin, phosphatidyl serine, phosphatidic acid, phosphatidyl inositol, phosphatidyl choline, and mixtures thereof.

25. The use of claim 24, wherein the polymerized phospholipid is polymerized lecithin.

26. The use of claim 21, wherein the coacervate has been dried to form a powder capable of being reconstituted by the addition of a physiologically-acceptable fluid.

27. A use for introducing a drug into the circulatory system of a mammal of a composition comprising an aqueous emulsion of coacervate-based matrix particles containing water, a surface active agent, and a drug solubilized therein; said coacervate system including a coacervate-based matrix containing the drug in aqueous solution; and a coacervate-based film encapsulating the matrix particles, said aqueous coacervate-based matrix particles comprising water selected from the group consisting of coacervate phase water, equilibrium phase water, and mixtures thereof and the drug.

28. The use of claim 27, wherein the drug comprises insulin.

29. The use of claim 27, wherein the drug comprises an atrial peptide.

30. A use for introducing a drug into the circulatory system of a mammal of a composition comprising an aqueous coacervate composition including water, a surface active agent, and a drug;
said coacervate composition including a coacervate-based matrix containing the drug in aqueous solution or aqueous suspension and a film encapsulating the matrix particles; said aqueous matrix particles containing water selected from the group consisting of coacervate phase water, equilibrium phase water, and mixtures thereof, and the drug solubilized or dispersed therein.

31. The use of claim 30, wherein the drug comprises an atrial peptide.

32. A method of preparing a composition containing one or more physiologically-active compounds for oral, tissue absorptive, inhalation, or parenteral administration to a mammal comprising mixing an aqueous solution of water, a surface active agent, a coacervating agent and a physiologically-active compound to form a two phase aqueous coacervate composition containing the physiologically-active compound in one or both of the two-phase bound as particles in a coacervate matrix and within a coacervate-based aqueous film containing the surface active agent, said coacervate-based matrix comprising water selected from the group consisting of coacervate phase water, equilibrium phase water, and mixtures thereof and the physiologically-active compound in solution within the matrix water; separating the particles; and adding a hydrocolloid to the particles in an amount of 2-20% w/v to form a gel-like surface film surrounding the matrix particles containing the physiologically-active compound.

33. The method of claim 32, further including emulsifying and microemulsifying the composition to form coacervate particles useful for oral administration.

34. The method of claim 32, further including emulsifying and microemulsifying the composition to form coacervate particles useful for oral administration having a particle size less than about 10 microns.

35. The method of claim 32, wherein the coacervate particles are microemulsified to less than about 2 microns.

36. The method of claim 32, wherein the coacervate particles are microemulsified to less than about 1 micron.

37. The method of claim 32, wherein the surface active agent is a polymerized phospholipid.

38. The method of claim 32, further including adding an anti-oxidant to the separated particles.

39. A use for introducing a drug into the circulatory system of a mammal of a composition comprising an aqueous coacervate system including water, a surface active agent, and a drug; said coacervate system including a coacervate-based matrix containing the drug and a film encapsulating the matrix particles; said aqueous coacervate-based matrix comprising water selected from the group consisting of coacervate phase water, equilibrium phase water, and mixtures thereof, and the drug in solution within the matrix water; separating the particles; and adding a hydrocolloid to the particles in an amount of 2-20% w/v to form a gel-like surface film surrounding the matrix particles containing the drug.

40. The use of claim 39 wherein the surface active agent comprises a protein, polymerized protein, phospholipid, polymerized phospholipid, or mixtures thereof.

41. The use of claim 39, wherein the drug comprises insulin.

42. The use of claim 39, wherein the drug comprises an atrial peptide.

43. A method of preparing a composition useful as a system to introduce and transport medically useful composition in the body of mammals;
said composition comprising an aqueous emulsion of particles of a coacervate-based matrix having one or more physiologically-active compounds incorporated therein; said coacervate-based matrix comprising water selected from the group consisting of coacervate phase water, equilibrium phase water, and mixtures thereof, said matrix particles including the physiologically-active compound solubilized in the matrix water;
said method comprising forming a mixture of one or more surface active agents, water and one or more physiologically-active compounds to produce a two phase aqueous coacervate composition containing said compounds, and emulsifying the composition under conditions to produce an aqueous emulsion of the coacervate-based matrix particles containing the physiologically-active compound.

44. A use for administering a physiologically-active compound to a mammal of a coacervate composition in a form suitable for topical administration containing a physiologically-active compound, said coacervate composition comprising an aqueous emulsion of coacervate-based matrix particles, said matrix particles comprising water, selected from the group consisting of coacervate phase water, equilibrium phase water, and mixtures thereof, said matrix particles including the physiologically-active compound solubilized in the matrix water.

45. A use for maintaining tissue or an organ of a mammal viable, outside of the mammal's body of a composition which has been formed by mixing one or more surface active agents and water to form a two phase aqueous coacervate composition, and emulsifying the composition to form an aqueous emulsion of coacervate-based matrix particles comprising water selected from the group consisting of coacervate phase water, equilibrium phase water, and mixtures thereof, said matrix particles having solubilized within the matrix water, a compound capable of extending the life of the organ when in contact therewith.